WO2020257173A1 - Method of treating the osteoarthritic joint - Google Patents
Method of treating the osteoarthritic joint Download PDFInfo
- Publication number
- WO2020257173A1 WO2020257173A1 PCT/US2020/037896 US2020037896W WO2020257173A1 WO 2020257173 A1 WO2020257173 A1 WO 2020257173A1 US 2020037896 W US2020037896 W US 2020037896W WO 2020257173 A1 WO2020257173 A1 WO 2020257173A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- baseline
- joint
- months
- points
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 175
- 230000003349 osteoarthritic effect Effects 0.000 title description 7
- 208000002193 Pain Diseases 0.000 claims abstract description 365
- 230000007423 decrease Effects 0.000 claims abstract description 269
- 201000004595 synovitis Diseases 0.000 claims abstract description 98
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims description 411
- 238000005259 measurement Methods 0.000 claims description 312
- 230000008859 change Effects 0.000 claims description 124
- 239000000090 biomarker Substances 0.000 claims description 113
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 73
- 210000000845 cartilage Anatomy 0.000 claims description 67
- 230000006872 improvement Effects 0.000 claims description 65
- 210000001179 synovial fluid Anatomy 0.000 claims description 47
- 210000005065 subchondral bone plate Anatomy 0.000 claims description 39
- 108090001005 Interleukin-6 Proteins 0.000 claims description 36
- 102000004889 Interleukin-6 Human genes 0.000 claims description 35
- 102100027995 Collagenase 3 Human genes 0.000 claims description 27
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims description 27
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 27
- 108050005238 Collagenase 3 Proteins 0.000 claims description 26
- 230000001976 improved effect Effects 0.000 claims description 26
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 25
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 25
- 102000003814 Interleukin-10 Human genes 0.000 claims description 25
- 108090000174 Interleukin-10 Proteins 0.000 claims description 25
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims description 24
- 101710187853 Macrophage metalloelastase Proteins 0.000 claims description 24
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 22
- 102100028848 Stromelysin-2 Human genes 0.000 claims description 22
- 101710108792 Stromelysin-2 Proteins 0.000 claims description 22
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 21
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 21
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 claims description 20
- 101710108790 Stromelysin-1 Proteins 0.000 claims description 20
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 19
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 19
- 108090000695 Cytokines Proteins 0.000 claims description 19
- 101000799972 Homo sapiens Alpha-2-macroglobulin Proteins 0.000 claims description 19
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims description 19
- 102000019034 Chemokines Human genes 0.000 claims description 18
- 108010012236 Chemokines Proteins 0.000 claims description 18
- 230000003247 decreasing effect Effects 0.000 claims description 18
- 108091005804 Peptidases Proteins 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 239000003102 growth factor Substances 0.000 claims description 16
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 16
- 238000002604 ultrasonography Methods 0.000 claims description 16
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 15
- 208000006820 Arthralgia Diseases 0.000 claims description 11
- 230000002411 adverse Effects 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 7
- 238000002591 computed tomography Methods 0.000 claims description 6
- 210000000544 articulatio talocruralis Anatomy 0.000 claims description 5
- 210000001145 finger joint Anatomy 0.000 claims description 5
- 210000000323 shoulder joint Anatomy 0.000 claims description 5
- 210000003857 wrist joint Anatomy 0.000 claims description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 239000000203 mixture Substances 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 46
- 210000003127 knee Anatomy 0.000 description 34
- 239000000902 placebo Substances 0.000 description 31
- 229940068196 placebo Drugs 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 22
- 238000012216 screening Methods 0.000 description 17
- 102000035195 Peptidases Human genes 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 12
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 9
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- -1 for example Proteins 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102100037362 Fibronectin Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 7
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 7
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 7
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 7
- 230000037182 bone density Effects 0.000 description 7
- 229940125381 senolytic agent Drugs 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 230000001174 ascending effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000001739 density measurement Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 210000001258 synovial membrane Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 206010031264 Osteonecrosis Diseases 0.000 description 4
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 4
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001612 chondrocyte Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 102000003815 Interleukin-11 Human genes 0.000 description 3
- 108090000177 Interleukin-11 Proteins 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 206010060820 Joint injury Diseases 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000008558 Osteophyte Diseases 0.000 description 3
- 102100032442 Protein S100-A8 Human genes 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 208000013201 Stress fracture Diseases 0.000 description 3
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 3
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 210000000521 femorotibial joint Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000024765 knee pain Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 231100001079 no serious adverse effect Toxicity 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000000014 opioid analgesic Substances 0.000 description 3
- 229940005483 opioid analgesics Drugs 0.000 description 3
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 3
- 230000008409 synovial inflammation Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 2
- 206010060968 Arthritis infective Diseases 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010052500 Calgranulin A Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000015872 Gaucher disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 101000947177 Homo sapiens C-X-C motif chemokine 6 Proteins 0.000 description 2
- 206010023230 Joint stiffness Diseases 0.000 description 2
- 208000016593 Knee injury Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000005268 Neurogenic Arthropathy Diseases 0.000 description 2
- 206010029326 Neuropathic arthropathy Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 208000027868 Paget disease Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000027077 Stickler syndrome Diseases 0.000 description 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 238000011882 arthroplasty Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 208000002849 chondrocalcinosis Diseases 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 210000005096 hematological system Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 208000027202 mammary Paget disease Diseases 0.000 description 2
- 230000005499 meniscus Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000011476 stem cell transplantation Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BDUHCSBCVGXTJM-WUFINQPMSA-N 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazol-1-yl]-oxomethyl]-2-piperazinone Chemical compound CC(C)OC1=CC(OC)=CC=C1C1=N[C@@H](C=2C=CC(Cl)=CC=2)[C@@H](C=2C=CC(Cl)=CC=2)N1C(=O)N1CC(=O)NCC1 BDUHCSBCVGXTJM-WUFINQPMSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014423 Chemokine CXCL6 Proteins 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101001073422 Homo sapiens Pigment epithelium-derived factor Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- 239000002172 P2Y12 inhibitor Substances 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 101710156987 Protein S100-A8 Proteins 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 1
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 1
- 230000007172 age related pathology Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 229950011318 cannabidiol Drugs 0.000 description 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229940029644 cymbalta Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 1
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 229940047562 eliquis Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 208000007420 pigmented villonodular synovitis Diseases 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 208000005528 popliteal cyst Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000009327 senolytic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 238000010414 shopping Methods 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 238000010415 tidying Methods 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- Osteoarthritis is a progressive joint disease in which the cartilage between bones in the joint breaks down causing joint pain and stiffness. Osteoarthritis is characterized by breakdown of the cartilage, deterioration of tendons and ligaments, and various degrees of inflammation in the synovium (the joint lining).
- the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound of Formula I results in a decrease in synovitis in the joint.
- the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle.
- the compound of Formula I is administered intra-articularly to the joint.
- the joint is a fern oro-tibial joint.
- the joint is a hip.
- the joint is spine, shoulder, ankle, wrist, or finger joint.
- the therapeutically effective dose of the compound of Formula I is administered as a single dose. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years.
- a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
- the baseline measurement is a baseline pain level.
- the baseline pain level is assessed using a pain assessment protocol.
- the pain assessment protocol is an 11- point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC) Index pain sub scale.
- the baseline measurement is a baseline functionality level.
- the baseline functionality level is assessed by WOMAC Index functional subscale.
- the baseline measurement is a baseline radiological categorization.
- the baseline radiological categorization is a Kellgren- Lawrence grade.
- the joint is the femoro-tibial joint.In some
- the baseline measurement is a baseline synovitis level.
- the baseline synovitis level of the patient is assessed using an 1 lpoint MRI score.
- the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient.
- the decrease in synovitis is by a decrease of at least 1 point as measured by the 1 lpoint MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 4 points, at least 5 points, at least 8 points, at least 9 points, at least 10 points, wherein the decrease is between 1-4 points, between 4-8 points, between 8-10 points, between 10-13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of between 1-4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the baseline measurement is a baseline synovial fluid level. In some embodiments, the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRI.
- the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level.
- the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
- the therapeutically effective dose of the compound of Formula I further results in a decrease in pain in the joint as compared to the baseline pain level.
- the decrease in pain in the joint is measured 12 weeks or measured 24 weeks after the compound of Formula I is administered to the patient.
- the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11- point NRS.
- the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40-50% as measured by the 11-point NRS or WOMAC Index pain subscale.
- the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
- the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale.
- the increase in functionality of the joint is measured 12 weeks or 24 weeks after the compound of Formula I is administered to the patient.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points.
- the baseline measurement is a baseline biomarker level.
- the baseline biomarker levels are measured from the patient’s synovial fluid.
- the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level.
- the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease.
- the biomarker comprises MMP- 10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C.
- the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, measured 12 weeks, or measured 24 weeks after the compound of Formula I is administered to the patient.
- the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression.
- the biomarker comprises a cytokine or chemokine such as CCL20, CCL19, IL-10, or IL-6.
- the biomarker comprises IL-6.
- the biomarker comprises a growth factor or adhesion molecule such as ICAM-1 or VEGF-C.
- the biomarker comprises a protease or protease inhibitor such as MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
- the therapeutically effective dose of the compound of Formula I is at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, or more.
- the therapeutically effective dose is in at least 8.5 ml, at least 9 mL, at least 10 mL, at least 11 mL, at least 12 mL, or more, of vehicle.
- the therapeutically effective dose results in an improved joint architecture measurement.
- a baseline joint architecture measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I, and wherein the improved joint architecture measurement comprises an improvement compared to the baseline joint architecture measurement.
- the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or X-ray device.
- the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement.
- the joint architecture measurement comprises a cartilage thickness measurement.
- the baseline joint architecture measurement comprises a baseline cartilage thickness measurement.
- the cartilage thickness measurement and the baseline cartilage thickness measurement are measured using X- ray or MRI.
- the cartilage thickness measurement comprises a joint space width (JSW) measurement.
- the baseline cartilage thickness measurement comprises a baseline JSW measurement.
- the improvement comprises an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01,
- the cartilage thickness measurement comprises a joint space narrowing (JSN) measurement.
- the baseline cartilage thickness measurement comprises a baseline JSN measurement.
- the improvement comprises reversing, stopping or decreasing the JSN measurement relative to the baseline JSN measurement.
- the joint architecture measurement comprises a subchondral bone surface area measurement.
- the baseline joint architecture measurement comprises a baseline subchondral bone surface area measurement.
- the improvement comprises a 50 Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the subchondral bone surface area measurement relative to the baseline subchondral bone surface area measurement.
- the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI.
- the joint architecture measurement comprises a Kellgren-Lawrence (KL) grade.
- the baseline joint architecture measurement comprises a baseline KL grade. In some embodiments, the improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more. In some embodiments, the joint architecture measurement comprises a progression through a KL grading scale. In some embodiments, the baseline joint architecture measurement comprises a baseline progression through the KL grading scale.
- the improvement comprises a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade, or comprises preventing the progression through the KL grading scale, as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
- the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound of Formula I results in a decrease in pain in the joint.
- the therapeutically effective dose of the compound of Formula I is at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, or more.
- the therapeutically effective dose is in at least 8.5 ml, at least 9 mL, at least 10 mL, at least 11 mL, at least 12 mL, or more, of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle. In some embodiments, the compound of Formula I is administered intra-articularly to the joint. In some embodiments, the joint is a femoro-tibial joint. In some embodiments, the joint is a hip. In some embodiments, the joint is spine, shoulder, ankle, wrist, or finger joint. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered as a single dose.
- the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years. In some embodiments, the patient is > 40 years of age. In some embodiments, the patient is ⁇ 85 years of age. In some embodiments, the patient is > 40 and ⁇ 85 years of age. In some embodiments, a baseline measurement is obtained from the patient prior to
- the baseline measurement is a baseline pain level.
- the joint pain and/or baseline pain level is assessed using a pain assessment protocol.
- the pain assessment protocol is an 11 -point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC) Index pain subscale.
- the baseline measurement is a baseline functionality level.
- the baseline functionality level is assessed by WOMAC Index functional subscale.
- the baseline measurement is a baseline radiological categorization.
- the baseline radiological categorization is a Kellgren-Lawrence grade.
- the joint is the fern oro-tibial joint.
- the baseline radiological categorization is a Kellgren-Lawrence grade.
- the joint is the fern oro-tibial joint.
- the baseline radiological categorization is a Kellgren-Lawrence grade.
- the joint is the fern oro-tibial joint.
- the baseline radiological categorization is a Kellgren-Lawrence grade.
- the measurement is a baseline synovial fluid level.
- the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRI.
- the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level.
- the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
- the decrease in pain in the joint is measured 12 weeks, or 24 weeks after the compound of Formula I is administered to the patient.
- the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11 -point NRS.
- the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40- 50% as measured by the 11 -point NRS or WOMAC Index pain subscale.
- the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
- the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale.
- the increase in functionality of the joint is measured 12 weeks or 24 weeks after the compound of Formula I is administered to the patient.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points.
- the baseline measurement is a baseline biomarker level.
- the baseline biomarker levels are measured from the patient’s synovial fluid.
- the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level.
- the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease.
- the biomarker comprises MMP-10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C.
- the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, or measured 12 weeks after the compound of Formula I is administered to the patient.
- the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression.
- PGIC global impression of change
- the biomarker comprises a cytokine or chemokine such as CCL20, CCL19, IL-10, or IL-6. In some embodiments, the biomarker comprises IL-6. In some embodiments, the biomarker comprises a growth factor or adhesion molecule such as ICAM-1 or VEGF-C. In some embodiments, the biomarker comprises a protease or protease inhibitor such as MMP-3, MMP-10, MMP-12, MMP-13, or A2M. In some embodiments, the therapeutically effective dose results in an improved joint architecture measurement.
- a baseline joint architecture measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I, and wherein the improved joint architecture measurement comprises an improvement compared to the baseline joint architecture measurement.
- the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or X-ray device.
- the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement.
- the joint architecture measurement comprises a cartilage thickness measurement.
- the baseline joint architecture measurement comprises a baseline cartilage thickness measurement.
- the cartilage thickness measurement and the baseline cartilage thickness measurement are measured using X-ray or MRI.
- the cartilage thickness measurement comprises a joint space width (JSW) measurement.
- the baseline cartilage thickness measurement comprises a baseline JSW measurement.
- the improvement comprises an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10,
- the cartilage thickness measurement comprises a joint space narrowing (JSN) measurement.
- the baseline cartilage thickness measurement comprises a baseline JSN measurement.
- the improvement comprises reversing, stopping or decreasing the JSN
- the joint architecture measurement comprises a subchondral bone surface area measurement.
- the baseline joint architecture measurement comprises a baseline subchondral bone surface area measurement.
- the improvement comprises a 50 Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the subchondral bone surface area measurement relative to the baseline subchondral bone surface area measurement.
- the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI.
- the joint architecture measurement comprises a Kellgren-Lawrence (KL) grade.
- the baseline joint architecture measurement comprises a baseline KL grade.
- the second KL grade Kellgren-Lawrence
- the joint architecture measurement comprises a progression through a KL grading scale.
- the baseline joint architecture measurement comprises a baseline progression through the KL grading scale.
- the improvement comprises a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade, or comprises preventing the progression through the KL grading scale, as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
- FIG. 1 illustrates a Phase I clinical trial single ascending dose study.
- FIG. 2 illustrates that no serious adverse events were observed in a Phase I clinical trial single ascending dose study.
- FIG. 3 illustrates a dose dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) sub scores.
- WOMAC Osteoarthritis Index
- FIG. 4 illustrates a grouped dosage dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by WOMAC subscores.
- FIG. 5 illustrates a dose dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by a numerical rating scale (NRS).
- NRS numerical rating scale
- FIG. 6 illustrates a grouped dosage dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by an NRS.
- FIG. 7 illustrates a dose dependent effect of the compound of Formula I in improving physical function in subjects with osteoarthritis, as assessed by WOMAC subscores.
- FIG. 8 illustrates a grouped dosage dependent effect of the compound of Formula I in improving physical function in subjects with osteoarthritis, as assessed by WOMAC subscores.
- FIG. 9A illustrates a beneficial effect on pain, as assessed by an NRS, of a single dose of the compound of Formula I relative to placebo.
- FIG. 9B illustrates a beneficial effect on pain, as assessed by WOMAC subscores, of a single dose of the compound of Formula I relative to placebo.
- FIG. 9C illustrates a beneficial effect on physical function, as assessed by WOMAC subscores, of a single dose of the compound of Formula I relative to placebo.
- FIG. 10 illustrates effects of the compound of Formula I relative to placebo on synovial fluid biomarkers levels.
- FIG. 11 illustrates a design for a Phase II clinical trial.
- FIG. 12 illustrates patient demographics in a clinical study.
- FIG. 13 illustrates baseline patient characteristics in a clinical study.
- FIG. 14 illustrates beneficial effects of the compound of Formula I in subjects with osteoarthritis, as assessed by Patient Global Impression of Change (PGIC) scores.
- PGIC Patient Global Impression of Change
- FIG. 15 illustrates effects of the compound of Formula I on pain and physical function in subjects with osteoarthritis, as assessed by WOMAC subscores.
- Osteoarthritis is a degenerative joint disease characterized by fibrillation of the cartilage at sites of high mechanical stress, bone sclerosis, and thickening of the synovium and the joint capsule. Fibrillation is a local surface disorganization involving splitting of the superficial layers of the cartilage. The early splitting is tangential with the cartilage surface, following the axes of the predominant collagen bundles. Collagen within the cartilage becomes disorganized, and proteoglycans are lost from the cartilage surface. In the absence of protective and lubricating effects of proteoglycans in a joint, collagen fibers become susceptible to degradation, and mechanical destruction ensues. Predisposing risk factors for developing osteoarthritis include increasing age, obesity, previous joint injury, overuse of the joint, weak thigh muscles, and genetics. It is a common cause of chronic disability in the elderly.
- Symptoms of osteoarthritis include sore or stiff joints, particularly the hips, knees, and lower back, after inactivity or overuse; stiffness after resting that goes away after movement; and pain that is worse after activity or toward the end of the day. Chronic inflammation is thought to be the main age-related factor that contributes to osteoarthritis.
- Senescent cells accumulate in tissues and organs of individuals as they age and are found at sites of age-related pathologies, including osteoarthritic joints. Senescent cells are believed important to inhibiting proliferation of dysfunctional or damaged cells and particularly to constraining development of malignancy (see, e.g., Campisi, Curr. Opin. Genet. Dev. 21 : 107-12 (2011); Campisi, Trends Cell Biol. 11 : S27-31 (2001); Prieur et al., Curr. Opin. Cell Biol.
- a senolytic agent is an agent that selectively (preferentially or to a greater degree) destroys, kills, removes, or facilitates selective destruction of senescent cells over non-senescent cells of the same cell type.
- a senolytic agent is used in an amount and for a time sufficient that selectively kills senescent cells but is insufficient to cause the death of a non-senescent cell.
- Senolytic agents prevent (i.e., reduces the likelihood of occurrence), reduces or inhibits loss or erosion of proteoglycan layers in a joint, reduces inflammation in the affected joint, and promotes (i.e., stimulates, enhances, induces) production of collagen (e.g., type 2 collagen). Removal of senescent cells causes a reduction in the amount (i.e., level) of inflammatory cytokines such as, for example, IL-6, produced in a joint and inflammation is reduced.
- inflammatory cytokines such as, for example, IL-6
- Methods are provided herein for treating osteoarthritis, for selectively killing senescent cells in an osteoarthritic joint of a subject, and/or inducing, for example, collagen (such as Type 2 collagen) production in the joint of a subject in need thereof by administering at least one senolytic agent (which may be combined with at least one pharmaceutically acceptable excipient to form a pharmaceutical composition) to the subject.
- a senolytic agent also may be used for decreasing (inhibiting, reducing) production of, for example, metalloproteinase 13 (MMP-13), which degrades collagen in a joint, and for restoring proteoglycan layer or inhibiting loss and/or degradation of the proteoglycan layer.
- MMP-13 metalloproteinase 13
- Treatment with the senolytic agent thereby also prevents (i.e., reduces likelihood of occurrence of), inhibits, or decreases erosion, or slows (i.e., decreases rate) erosion of the bone.
- the methods comprising administering a senolytic agent can reduce joint pain and are therefore useful for pain management of osteoarthritic joints.
- the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound results in a decrease in synovitis in the joint.
- the compound of Formula I is shown in the structure above and is also known as 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(l- methylethoxy)phenyl]-lH-imidazol-l-yl]carbonyl]-2-piperazinone.
- the present disclosure further contemplates that therapeutically effective doses of cytotoxins, or cytostatic agents of which the compound of Formula I is an example, may be efficacious in treating an osteoarthritic joint as described herein.
- the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 6 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 12 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula
- the therapeutically effective dose of the compound of Formula I is 2 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 9 mL of vehicle. In some embodiments, the
- therapeutically effective dose of the compound of Formula I is 2 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in
- the therapeutically effective dose of the compound of Formula I is 2 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 16 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 6 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 12 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 2 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 3 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 9 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 3 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 16 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 6 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 12 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 2 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 4 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 9 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 4 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 16 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 6 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 12 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 2 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 6 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 9 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 6 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 16 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 6 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 12 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 2 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 8 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 9 mL of vehicle.
- the therapeutically effective dose of the compound of Formula I is 8 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 16 mL of vehicle.
- the compound of Formula I is administered locally to the joint. In some embodiments, the compound of Formula I is administered intra-articularly to the joint.
- the joint is a fern oro-tibial joint. In some embodiments, the joint is a hip. In some embodiments, the joint is spine, shoulder, ankle, wrist, or finger joint. In some embodiments, the joint is the spine. In some embodiments, the joint is the shoulder. In some embodiments, the joint is the ankle. In some embodiments, the joint is the wrist. In some embodiments, the joint is the finger.
- the therapeutically effective dose of the compound of Formula I is administered as a single dose. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months. In some embodiments, the
- therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years.
- the joint has senescent cells.
- the senescent cells are senescent chondrocytes or senescent epithelial cells, or senescent synoviocytes.
- the senescent cells are senescent chondrocytes.
- the senescent cells are senescent epithelial cells.
- the senescent cells are senescent synoviocytes.
- Senescent cells may be detected by morphology (as viewed by microscopy, for example); production of senescence associated markers such as, for example,
- senescence-associated b-galactosidase SA-P-gal
- r ⁇ 11 ⁇ 43 r ⁇ 11 ⁇ 43
- p21 p21
- PAI-1 p21
- SASP factors e.g IL-6, MMP3
- the presence of the senescent cell-associated polypeptide pl6 can be determined by standard immunochemistry, such as immunoblotting analysis. Expression of pl6 mRNA in a cell can be measured by a variety of techniques including quantitative PCR.
- the term“individual,”“patient,” or“subject” refers to individuals diagnosed with, suspected of being afflicted with, or at-risk of developing at least one disease for which the described compositions and method are useful for treating.
- the individual is a mammal.
- the mammal is a human.
- the patient is > 40 years of age. In some embodiments, the patient is > 45 years of age. In some embodiments, the patient is > 50 years of age. In some embodiments, the patient is > 55 years of age. In some embodiments, the patient is > 60 years of age. In some embodiments, the patient is ⁇ 85 years of age. In some embodiments, the patient is ⁇ 80 years of age. In some embodiments, the patient is ⁇ 75 years of age. In some embodiments, the patient is ⁇ 70 years of age. In some embodiments, the patient is ⁇ 75 years of age. In some embodiments, the patient is > 40 and less than ⁇ 85 years of age. In some embodiments, the patient is > 45 and less than ⁇ 80 years of age. In some embodiments, the patient is > 50 and less than ⁇ 75 years of age. In some embodiments, the patient is > 55 and less than ⁇ 70 years of age.
- a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
- the baseline measurement is a baseline pain level.
- the baseline pain level is assessed using a pain assessment protocol.
- the pain assessment protocol is an 11 -point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC) Index pain subscale.
- the pain assessment protocol is the 11 -point Numeric Rating Scale (NRS).
- the 11 -point Numeric Rating Scale (NRS) comprises asking the patient to rate their pain on a scale from 0 to 10 during, for example but not limited to, a 24 hour period, in which 0 is no pain, and 10 represents the worst possible pain.
- the baseline pain level of the patient is a mean of > 3 and ⁇ 9 points on the 11- point NRS.
- the baseline pain level of the patient is a mean of > 4 and ⁇ 9 points on the 11-point NRS.
- the baseline pain level of the patient is a mean of > 5 and ⁇ 9 points on the 11-point NRS.
- the baseline pain level of the patient is a mean of > 3 and ⁇ 8 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 4 and ⁇ 8 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 5 and ⁇ 8 points on the 11- point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 3 and ⁇ 7 points on the 11 -point NRS In some embodiments, the baseline pain level of the patient is a mean of > 4 and ⁇ 7 points on the 11 -point NRS.
- the baseline pain level of the patient is a mean of > 5 and ⁇ 7 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 4 and ⁇ 5 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 5 and ⁇ 6 points on the 11- point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 6 and ⁇ 7 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 7 and ⁇ 8 points on the 11 -point NRS.
- the baseline pain level of the patient is a mean of > 8 and ⁇ 9 points on the 11 -point NRS.
- the term “about” refers to an amount that is near the stated amount by 10% or less.
- the baseline pain level of the patient is a mean of about 4 on the 11-point NRS.
- the baseline pain level of the patient is a mean of about 5 on the 11-point NRS.
- the baseline pain level of the patient is a mean of about 6 on the 11 -point NRS.
- the baseline pain level of the patient is a mean of about 7 on the 11-point NRS.
- the baseline pain level of the patient is a mean of about 8 on the 11-point NRS.
- the baseline pain level of the patient is a mean of about 9 on the 11 -point NRS.
- the pain assessment protocol is the WOMAC pain subscale.
- the WOMAC Index pain subscale comprises a set of questionnaires in which a health professional evaluates the condition of the patient.
- the questionnaire contains 5 questions pertaining to the amount of pain that the patient feels during walking, using stairs, in bed, sitting, and standing. Each question is scored on a scale of 0 to 4 which correspond to: none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores are summed up, with a total possible score of 0-20 for the pain subscale.
- the baseline pain level of the patient is > 6 on the WOMAC pain subscale.
- the baseline pain level of the patient is > 6 and less than ⁇ _17 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than ⁇ 16 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than ⁇ _15 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than ⁇ _14 on the WOMAC pain subscale. In some
- the baseline pain level of the patient is > 6 and less than ⁇ _13 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than ⁇ 12 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than ⁇ _11 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than ⁇ _10 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 6. In some embodiments, the baseline pain level of the patient is 7 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 8 on the WOMAC pain subscale.
- the baseline pain level of the patient is 9 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 10 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 11 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 12 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 13 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 14 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 15 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 16 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 17 on the WOMAC pain sub scale. In some embodiments, the baseline pain level of the patient is 18 on the WOMAC pain sub scale. In some
- the baseline pain level of the patient is 19 on the WOMAC pain subscale.
- the baseline measurement is a baseline functionality level.
- the baseline functionality level is assessed by WOMAC Index functionality subscale.
- the baseline functionality level is assessed by WOMAC Index functional subscale.
- the WOMAC Index functional subscale comprises a set of questionnaires in which a health professional evaluates the condition of the patient.
- the questionnaire contains 17 questions such as, for example: the degree of difficulty with performing the following: A. Descending stairs, B. Ascending stairs, C. Rising from sitting, D. Standing, E. Bending to floor, F. Walking on a flat surface, G. Getting in or out of a car, H. Going shopping, I. Putting on socks/stockings, J.
- each question is scored on a scale of 0 to 4 which correspond to: none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores are summed up, with a total possible score of 0-68 for the WOMAC functional subscale.
- the baseline functionality level of the patient is > 17 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 18 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 19 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 20 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 21 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 22 and ⁇ 68.
- the baseline functionality level of the patient is > 23 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 24 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 25 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 26 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 27 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 28 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 29 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 30 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 31 and ⁇ 68.
- the baseline functionality level of the patient is > 32 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 33 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 34 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 35 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 36 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 37 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 38 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 39 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 40 and ⁇ 68.
- the baseline functionality level of the patient is > 41 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 42 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 43 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 44 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 45 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 46 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 47 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 48 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 49 and ⁇ 68.
- the baseline functionality level of the patient is > 30 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 31 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 32 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 33 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 34 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 35 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 36 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 37 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 38 and ⁇ 68.
- the baseline functionality level of the patient is > 39 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 50 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 51 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 52 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 53 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 54 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 55 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 56 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 57 and ⁇ 68.
- the baseline functionality level of the patient is > 58 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 59 and ⁇ 68. In some embodiments, the baseline functionality level of the patient is > 60 and ⁇ 68.
- the baseline measurement is a baseline stiffness level.
- the baseline stiffness level is assessed by WOMAC Index stiffness subscale.
- the WOMAC Index stiffness subscale comprises a set of questionnaires in which a health professional evaluates the condition of the patient.
- the questionnaire contains 2 questions, such as, for example: How severe is your stiffness after first awakening in the morning? How severe is your stiffness after sitting, lying, or resting later in the day? Each question is scored on a scale of 0 to 4 which correspond to: none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores are summed up, with a total possible score of 0-8 for the WOMAC stiffness subscale.
- the baseline stiffness level of the patient is > 1 and ⁇ 8. In some embodiments, the baseline stiffness level of the patient is > 1 and ⁇ 7. In some embodiments, the baseline stiffness level of the patient is > 1 and ⁇ 6. In some embodiments, the baseline stiffness level of the patient is > 1 and ⁇ 5. In some embodiments, the baseline stiffness level of the patient is > 1 and ⁇ 4. In some embodiments, the baseline stiffness level of the patient is > 1 and ⁇ 3. In some embodiments, the baseline stiffness level of the patient is 1. In some embodiments, the baseline stiffness level of the patient is 2. In some embodiments, the baseline stiffness level of the patient is 3. In some embodiments, the baseline stiffness level of the patient is 4. In some embodiments, the baseline stiffness level of the patient is 5. In some embodiments, the baseline stiffness level of the patient is 6. In some embodiments, the baseline stiffness level of the patient is 7. In some embodiments, the baseline stiffness level of the patient is 8.
- the baseline measurement is a baseline radiological
- the baseline radiological categorization is a Kellgren- Lawrence grade.
- the Kellgren-Lawrence grading system is a radiological classification system for assessing severity of osteoarthritis.
- the grading system categorizes osteoarthritis severity according to the following grades: grade 0 - no radiographic features of OA are present, grade 1- doubtful joint space narrowing (JSN) and possible osteophytic lipping, grade 2 - definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph, grade 3 - multiple osteophytes, definite JSN, sclerosis, possible bony deformity, grade 4 - large osteophytes, marked JSN, severe sclerosis and definite bony deformity.
- JSN doubtful joint space narrowing
- the baseline radiological categorization of the patient is 1 through 4 on the Kellgren-Lawrence grading system. In some embodiments, the baseline radiological categorization of the patient is 1 on the Kellgren-Lawrence grading system. In some embodiments, the baseline radiological categorization of the patient is 2 on the Kellgren-Lawrence grading system. In some
- the baseline radiological categorization of the patient is 3 on the Kellgren- Lawrence grading system. In some embodiments, the baseline radiological categorization of the patient is 4 on the Kellgren-Lawrence grading system. In some embodiments, the baseline radiological categorization is of the fern oro-tibial joint.
- the baseline measurement is a baseline synovitis level.
- the baseline synovitis level is assessed using an 11 point MRI score based on Guermazi et al. [assessment of synovitis with contrast-enhanced MRI using a while-joint semiquantitiative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study.” Ann Rheum Dis 2011;70:805-811.
- 11 point MRI reading 9 anatomical sites as outlined in Table 1 are evaluated for synovitis. If present, Baker’s cysts or loose bodies, are scored in addition to the 9 anatomical locations.
- Synovitis comprises an inflammation of the synovial membrane and is characterized on MRI by thickening and enhancement after administration of intravenous contrast agent.
- Each site as outlined in Table 1 is scored based on the maximal thickness in any slice at each site as follows: grade 0 if ⁇ 2 mm, grade 1 if 2-4 mm and grade 2 if >4 mm (as shown in Table 2) with a maximal score of 22. The scores are summed to calculate a synovitis level (as shown in Table 3).
- the baseline synovitis level of the patient is at least 7 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 8 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 9 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 10 as measured by the 11 point MRI score.
- the baseline synovitis level of the patient is at least 11 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 12 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 13 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 14 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 15 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 16 as measured by the 11 point MRI score.
- the baseline synovitis level of the patient is > 7 and ⁇ 18 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is > 8 and ⁇ 17 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is > 8 and ⁇ 16 as measured by the 11 point MRI score.
- the baseline measurement is a baseline joint architecture measurement.
- joint architecture refers to bone structure, cartilage structure, joint space width (JSW), or joint space narrowing (JSN), in the joint.
- the baseline joint architecture measurement is a baseline cartilage thickness measurement, a baseline subchondral bone surface area measurement, a baseline Kellgren- Lawrence (KL) grade, or a baseline progression through a KL grading scale.
- KL Kellgren- Lawrence
- the baseline joint architecture measurement is baseline bone, tendon, or meniscus measurement. In some embodiments, the baseline joint architecture measurement is measured using MRI, ultrasound, computed tomography, or an X-ray device. In some embodiments, the joint of the baseline joint architecture measurement is a knee. In some embodiments, the knee is the patient’s left knee. In some embodiments, the knee is the patient’s right knee.
- the baseline joint architecture measurement is a baseline cartilage thickness measurement.
- the baseline cartilage thickness measurement is measured using X-ray or MRI.
- the baseline cartilage thickness measurement is a baseline joint space width (JSW) measurement or a baseline joint space narrowing (JSN) measurement.
- the baseline cartilage thickness measurement is a baseline joint space width (JSW) measurement.
- the baseline JSW measurement is a baseline medial JSW measurement.
- the baseline JSW measurement is a baseline lateral JSW measurement.
- the baseline JSW is a baseline minimum JSW.
- the baseline minimum JSW is the shortest visible distance between the femoral condyle and the tibial plateau.
- the baseline JSW measurement is 2 mm. In some embodiments, the baseline JSW measurement is 2.5 mm. In some embodiments, the baseline JSW measurement is 3 mm. In some embodiments, the baseline JSW measurement is 3.5 mm. In some embodiments, the baseline JSW measurement is 4 mm. In some embodiments, the baseline JSW measurement is 4.5 mm. In some embodiments, the baseline JSW measurement is 5 mm. In some embodiments, the baseline JSW measurement is 5.5 mm. In some embodiments, the baseline JSW measurement is 6 mm. In some embodiments, the baseline JSW measurement is 6.5 mm. In some embodiments, the baseline JSW measurement is 7 mm.
- the baseline cartilage thickness measurement is a baseline joint space narrowing (JSN) measurement.
- JSN joint space narrowing
- the baseline JSN measurement is a baseline change in JSW.
- the baseline JSW measurement is measured based on longitudinal changes in a minimum JSW measurement.
- the baseline change in JSW of the baseline JSN measurement is 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12,
- the baseline JSN measurement is a baseline change in JSW over time.
- the time of the baseline change in JSW over time is 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.
- the baseline JSN measurement may be 0.02 to 0.05 mm per year.
- the baseline joint architecture measurement is a baseline subchondral bone surface area measurement.
- the baseline subchondral bone surface area measurement is measured using X-ray or MRI.
- the baseline subchondral bone surface area measurement is a baseline bone density.
- the baseline bone density is 200 Hounsfield Units (HU), 250 HU, 300 HU, 350
- the baseline subchondral bone surface area measurement is a baseline number of cystic areas. In some embodiments, the baseline subchondral bone surface area measurement is a baseline number of cystic areas is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more. In some embodiments, the cystic areas comprise low-density bone areas.
- the baseline joint architecture measurement is a baseline
- the baseline KL grade is 1. In some embodiments, the baseline KL grade is 2. In some embodiments, the baseline KL grade is 3. In some embodiments, the baseline KL grade is 4. In some embodiments, the baseline KL grade is 2 or 3. In some embodiments, the baseline KL grade is 3 or 4. In some embodiments, the baseline KL grade is 2, 3 or 4.
- the baseline joint architecture measurement is a baseline progression through a KL grading scale.
- the baseline progression through the KL grading scale comprises a KL grade increase.
- the KL grade increase is 0.5.
- the KL grade increase is 1.
- the KL grade increase is 2.
- the KL grade increase is 3.
- the KL grade increase of the baseline progression through the KL grading scale is over time. In some embodiments, time of the KL grade increase is 1 month, 2 months, 3 months, 4 months,
- the baseline progression through a KL grading scale may be a 0.5 grade increase per year.
- efficacy of the therapeutically effective dose of the compound of Formula I is assessed.
- a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
- the baseline measurement is a baseline synovitis level.
- the baseline synovitis level is assessed using an 11 point MRI score.
- the decrease in synovitis in the joint is measured by the 11-point MRI score.
- the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 1 point as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 4 points, at least 5 points, at least 8 points, at least 9 points, at least 10 points, wherein the decrease is between 1-4 points, between 4-8 points, between 8-10 points, between 10-13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of between 1-4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 2 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 3 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 5 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 6 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 7 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 8 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 9 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 10 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 11 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 12 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 14 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 15 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 16 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 17 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis is by a decrease of at least 18 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 19 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 20 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
- the decrease in synovitis in the joint is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 1 year after the compound of Formula I is administered to the patient.
- the baseline measurement is a baseline synovial fluid level.
- the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRF.
- the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level.
- the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
- the decrease in synovial fluid in the joint is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 10 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 12 weeks after the compound of Formula I is administered to the patient.
- the decrease in synovial fluid in the joint is measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 1 year after the compound of Formula I is administered to the patient.
- efficacy of the therapeutically effective dose of the compound of Formula I is assessed.
- a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
- the baseline measurement is a pain level.
- the therapeutically effective dose of the compound of Formula I further results in a decrease in pain in the joint as compared to the baseline pain level.
- the decrease in pain in the joint is measured 12 weeks after the compound of Formula I is administered to the patient.
- the decrease in pain in the joint is measured 24 weeks after the compound of Formula I is administered to the patient.
- the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 1 point as assessed by the 11 -point NRS.
- the decrease in pain in the joint is a change from the baseline pain level of about 2 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 3 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 4 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 5 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 6 points as assessed by the 11 -point NRS.
- the decrease in pain in the joint is a change from the baseline pain level of about 7 points as assessed by the 11- point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 8 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 9 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 10 points as assessed by the 11 -point NRS.
- the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 0.5 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 1 point as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 2 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 3 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 4 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 5 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 6 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 7 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 8 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 9 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 10 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 11 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 12 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 13 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 14 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 15 points as assessed by the WOMAC Index pain subscale.
- the decrease in pain in the joint is a change from the baseline pain level of about 16 points as assessed by the WOMAC Index pain sub scale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 17 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 18 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 19 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 20 points as assessed by the WOMAC Index pain sub scale.
- the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40-50% as measured by the 11 -point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 50% as measured by the 11 -point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 40% as measured by the 11 -point NRS or
- the decrease in pain in the joint is a change from the baseline pain level of about 30% as measured by the 11 -point NRS or
- the decrease in pain in the joint is a change from the baseline pain level of about 20% as measured by the 11 -point NRS or
- the decrease in pain in the joint is a change from the baseline pain level of about 10% as measured by the 11 -point NRS or
- the decrease in pain in the joint is a change from the baseline pain level of about 5% as measured by the 11 -point NRS or WOMAC Index pain subscale.
- the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
- the decrease in pain is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 1 year after the compound of Formula I is administered to the patient.
- the decrease the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
- the decrease the decrease in pain relative to the baseline pain level lasts about 3 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 4 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 5 months.
- the decrease the decrease in pain relative to the baseline pain level lasts about 6 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 7 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 8 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 9 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 10 months. In some embodiments,
- the decrease the decrease in pain relative to the baseline pain level lasts about 11 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 1 year. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 2 years. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 3 years. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 4 years. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 5 years.
- the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale.
- the increase in functionality of the joint is measured 12 weeks after the compound of Formula I is administered to the patient.
- the increase in functionality of the joint is measured 24 weeks after the compound of Formula I is administered to the patient.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 0.5 points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 1 point.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 2 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 3 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 4 points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 5 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 6 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 7 points.
- the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 8 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 9 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 10 points.
- the increase in functionality of the joint is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 1 year after the compound of Formula I is administered to the patient.
- the baseline measurement is a baseline stiffness level.
- the baseline stiffness level is assessed by WOMAC Index stiffness subscale.
- the therapeutically effective dose of the compound of Formula I results in a decrease stiffness in the joint as assessed by WOMAC Index stiffness subscale relative to the baseline stiffness level.
- the decrease in stiffness in the joint is a change from the baseline stiffness level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points as assessed by WOMAC Index stiffness subscale.
- the decrease in stiffness in the joint is measured 24 weeks, or 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
- a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula F
- the baseline measurement is a baseline biomarker level.
- the baseline biomarker levels are measured from the patient’s synovial fluid.
- the baseline biomarker levels are measured from the patient’s plasma.
- the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level.
- the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease.
- the modulation of the biomarker levels relative to the baseline biomarker levels is an increase.
- the biomarker comprises MMP- 10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C.
- the biomarker comprises CXCL10, CCL20, CCL19, CXCL1, CD14, Complement protein C3, GDF15, IL-10, IL-6, fibronectin, ICAM-1, VEGF-C, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M.
- the biomarker comprises CCL20, CCL19, IL-10, IL-6, ICAM-1, VEGF-C, MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
- the biomarker comprises IL-6.
- the biomarker is not limited to these examples.
- the biomarker comprises a cytokine or chemokine.
- the cytokine or chemokine comprises C-X-C motif chemokine 10 (CXCL10; Perrott et al. Geroscience 2017; Kisand et al. Osteoarthritis Cartilage 2018), Chemokine (C-C motif) ligand 20 (CCL20; Freund et al. Trends Mol Med. 2010; Alaaeddine et al. Inflamm Res. 2015), Chemokine (C-C motif) ligand 19 (CCL19; Carter et al. Genome Biol. 2005; Robinson et al. Nat Rev Rheumatol.
- the cytokine or chemokine comprises CXCL10, CCL20, CCL19, CXCL1, CD14, C3, GDF15, IL-10, IL-6, or a combination thereof.
- the cytokine or chemokine comprises CCL20, CCL19, IL-10, IL-6, or a combination thereof. In some embodiments, the cytokine or chemokine comprises IL-6. In some embodiments, the cytokine or chemokine is selected from the group consisting of CXCL10, CCL20, CCL19, IL-11, S100A8, CXCL1,
- the cytokine or chemokine is selected from the group consisting of CXCL10, CCL20, CCL19, CXCL1, CD14, C3, GDF15, IL-10, and IL-6. In some embodiments, the cytokine or chemokine is selected from the group consisting of CCL20, CCL19, IL-10, and IL-6. In some embodiments, the cytokine or chemokine is IL-6.
- the biomarker comprises a growth factor or adhesion molecule.
- the growth factor or adhesion molecule comprises fibronectin (Scuderi et al. J Bone Joint Surg Am. 2011), intercellular adhesion molecule 1 (ICAM-1; Freund et al.
- the growth factor or adhesion molecule comprises fibronectin, ICAM-1, VEGF-C, or a combination thereof. In some embodiments, the growth factor or adhesion molecule comprises ICAM-1, VEGF-C, or a combination thereof.
- the growth factor or adhesion molecule is selected from the group consisting of ICAM-1, VEGF-C, SERPINFl, and PEDF. In some embodiments, the growth factor or adhesion molecule is selected from the group consisting of fibronectin, ICAM-1, and VEGF-C. In some embodiments, the growth factor or adhesion molecule is selected from the group consisting of ICAM-1 and VEGF-C.
- the biomarker comprises a protease or a protease inhibitor.
- the protease or protease inhibitor comprises matrix metalloproteinase- 1 (MMP-1; Nagase et al. Matrix Suppl. 1992; Freund et al. Trends Mol Med. 2010; Wyatt et al. Osteoarthritis Cartilage 2018), matrix metalloproteinase-3 (MMP-3; Sellers and Murphy Int Rev Connect Tissue Res. 1981; Freund et al. Trends Mol Med. 2010; Cevidanes et al.
- Osteoarthritis Cartilage 2014 matrix metalloproteinase- 13 (MMP-13; Mitchell et al. J Clin Invest. 1996; Reboul et al. J Clin Invest. 1996; Freund et al. Trends Mol Med. 2010; Ma et al. Connect Tissue Res. 2019), TEMP metallopeptidase inhibitor 1 (TEMPI; Freund et al. Trends Mol Med. 2010; Cevidanes et al. Osteoarthritis Cartilage 2014), A2M (Chou et al. Osteoarthritis Cartilage 2018; Zhao et al. J Cell Biochem. 2015) or a combination thereof.
- MMP-13 matrix metalloproteinase- 13
- TEMPI TEMP metallopeptidase inhibitor 1
- A2M Cevidanes et al. Osteoarthritis Cartilage 2018; Zhao et al. J Cell Biochem. 2015
- the protease or protease inhibitor comprises MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TEMP-1, A2M, or a combination thereof. In some embodiments, the protease or protease inhibitor comprises MMP-3, MMP-10, MMP-12, MMP-13, A2M, or a combination thereof. In some embodiments, the protease or protease inhibitor is selected from the group consisting of MMP-1, MMP-3, MMP-13, and TEMPI. In some embodiments, the protease or protease inhibitor is selected from the group consisting of MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TEMP-1, and A2M. In some embodiments, the protease or protease inhibitor is selected from the group consisting of MMP-3, MMP-10, MMP-12, MMP-13, and A2M.
- the biomarker comprises a cytokine or chemokine, a growth factor or adhesion molecule, or a protease or a protease inhibitor.
- cytokines, chemokines, growth factors, adhesion molecules, proteases, and protease inhibitors include but are not limited to those provided above.
- the biomarker comprises a biomarker other than a cytokine, chemokine, growth factor, adhesion molecule, protease, or protease inhibitor.
- the biomarker comprises a cytokine or chemokine, or a growth factor or adhesion molecule.
- the biomarker may comprise CXCL10, CCL20, CCL19, CXCL1, CD 14, C3, GDF15, IL-10, IL-6, fibronectin, ICAM-1, or VEGF-C.
- the biomarker comprises CCL20, CCL19, IL-10, IL-6, ICAM-1, or VEGF-C.
- the biomarker comprises IL-6, fibronectin, ICAM-1, or VEGF-C.
- the biomarker comprises IL-6, ICAM-1, or VEGF-C.
- the biomarker comprises a cytokine or chemokine, or a protease or a protease inhibitor.
- the biomarker may comprise CXCL10, CCL20, CCL19, CXCL1, CD 14, C3, GDF15, IL-10, IL-6, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M.
- the biomarker comprises CCL20, CCL19, IL-10, IL- 6, MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
- the biomarker comprises IL-6, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M. In some embodiments, the biomarker comprises IL-6, MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
- the biomarker comprises a growth factor or adhesion molecule, or a protease or a protease inhibitor.
- the biomarker may comprise fibronectin, ICAM-1, VEGF-C, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M.
- the biomarker comprises ICAM-1, VEGF-C, MMP-3, MMP-10, MMP-12, MMP- 13, or A2M.
- the level of CCL20 is decreased relative to a baseline CCL20 level.
- the level of CCL19 is increased relative to a baseline CCL19 level.
- the level of IL-10 is decreased relative to a baseline IL-10 level.
- the level of IL-6 is decreased relative to a baseline IL-6 level.
- the level of MMP-3 is increased relative to a baseline MMP-3 level.
- the level of MMP-10 is decreased relative to a baseline MMP-10 level.
- the level of MMP-12 is decreased relative to a baseline MMP-12 level.
- the level of MMP-13 is decreased relative to a baseline MMP-13 level.
- the level of A2M is increased relative to a baseline A2M level.
- the level of ICAM-1 is increased relative to a baseline ICAM-1 level.
- the level of VEGF-C is decreased relative to a baseline VEGF-C level.
- the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, measured 12 weeks, or measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 6 weeks after the compound of Formula I is administered to the patient.
- the modulation of the biomarker relative to the baseline biomarker level is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 10 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 1 year after the compound of Formula I is administered to the patient.
- the contemplated treatment methods result in a "much improved” or “very much improved” patient global impression of change (PGIC) for the patient.
- PGIC is a patient-reported outcome of how a treatment is progressing, and can be used as an indicator of meaningful change in treatments, such as for example, osteoarthritic pain.
- the PGIC is scored on a 5 level scale, ranging from (5): minimally worse; (4): no change; (3): minimally improved; (2) much improved; and (1) very much improved.
- the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression.
- PGIC global impression of change
- the baseline measurement is a joint architecture measurement.
- the therapeutically effective dose of the compound of Formula I further results in an improvement in the joint architecture measurement compared to the baseline joint architecture measurement.
- the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement.
- the improvement in the joint architecture measurement is measured 24 weeks, or 12 weeks after the compound of Formula I is administered to the patient.
- the joint architecture measurement is a cartilage thickness measurement, a subchondral bone surface area measurement, a Kellgren- Lawrence (KL) grade, or a progression through a KL grading scale.
- the joint architecture measurement is bone, tendon, or meniscus measurement.
- the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or an X-ray device.
- the joint of the joint architecture measurement is a knee.
- the knee is the patient’s left knee.
- the knee is the patient’s right knee.
- the baseline joint architecture measurement is a baseline cartilage thickness measurement. In some embodiments, the joint architecture measurement is a cartilage thickness measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the cartilage thickness measurement compared to the baseline cartilage thickness measurement. In some embodiments, the cartilage thickness measurement is measured using X-ray or MRI.
- the baseline cartilage thickness measurement is a baseline joint space width (JSW) measurement.
- the cartilage thickness measurement is a JSW measurement.
- the therapeutically effective dose of the compound of Formula I results in an improvement in the JSW measurement compared to the baseline JSW measurement.
- the JSW measurement is a medial JSW measurement.
- the JSW measurement is a lateral JSW measurement.
- the JSW measurement is a minimum JSW. In some embodiments, the JSW is the shortest visible distance between the femoral condyle and the tibial plateau.
- the improvement is an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,
- the improvement may be an increase in the JSW measurement relative to the baseline JSW measurement of 0.01-2.00 mm, 0.02-1.00 mm, or 0.05-0.50 mm, or 0.10-0.20 mm.
- the improvement is an increase in the JSW measurement relative to the baseline JSW measurement of 0.1-0.6 mm.
- the increase in the JSW measurement is at least 0.01 mm.
- the increase in the JSW measurement is at least 0.05 mm.
- the increase in the JSW measurement is at least 0.10 mm.
- the increase in the JSW measurement is at least 0.25 mm. In some embodiments, the increase in the JSW measurement is at least 0.50 mm. In some embodiments, the increase in the JSW measurement is at least 1.00 mm. In some embodiments, the increase in the JSW measurement is at least 1.50 mm. In some embodiments, the increase in the JSW measurement is at least 2.00 mm. In some embodiments, the increase in the JSW measurement is at least 2.50 mm.
- the baseline cartilage thickness measurement is a baseline joint space narrowing (JSN) measurement. In some embodiments, the cartilage thickness
- the measurement is a JSN measurement.
- the therapeutically effective dose of the compound of Formula I results in an improvement in the JSN measurement compared to the baseline JSN measurement.
- the improvement comprises reversing, stopping or decreasing the JSN measurement relative to the baseline JSN measurement.
- the JSW measurement is measured based on longitudinal changes in a minimum JSW measurement.
- the change in JSW of the JSN measurement is 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0 mm, less than a change in a JSW of a baseline JSN measurement.
- the therapeutically effective dose of the compound of Formula I decreases JSN by 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0 mm, or more.
- the therapeutically effective dose of the compound of Formula I may decrease JSN by 0.05-2.00 mm, 0.1-0.6 mm, 0.10-1.50 mm, or 0.20-1.00 mm.
- the JSN measurement is a change in JSW over time.
- the time of the change in JSW over time is 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years.
- the improvement may be a JSN measurement of 0.02 to 0.05 mm per year less than the baseline JSN measurement.
- the baseline joint architecture measurement is a baseline subchondral bone surface area measurement. In some embodiments, the joint architecture measurement is a subchondral bone surface area measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the subchondral bone surface area measurement compared to the baseline subchondral bone surface area measurement. In some embodiments, the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI.
- the subchondral bone surface area measurement is a bone density measurement
- the improvement is an increase in the bone density measurement compared to a baseline bone density measurement. In some embodiments, the improvement is a 50
- the subchondral bone surface area measurement is a number of cystic areas compared to a baseline number of cystic areas.
- the improvement is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, less cystic areas than the baseline number of cystic areas.
- the cystic areas comprise low-density bone areas.
- the baseline joint architecture measurement is a baseline KL grade.
- the joint architecture measurement is a Kellgren-Lawrence (KL) grade.
- the therapeutically effective dose of the compound of Formula I results in an improvement in the KL grade compared to the baseline KL grade.
- the improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more.
- the improvement is a decrease in the KL grade relative to the baseline KL grade by half a KL grade.
- the improvement is a decrease in the KL grade relative to the baseline KL grade by one KL grade.
- the improvement is a decrease in the KL grade relative to the baseline KL grade by two KL grades. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by three KL grades. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by four KL grades. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by 0.5-4 KL grades.
- the baseline joint architecture measurement is a baseline progression through the KL grading scale. In some embodiments, the joint architecture measurement is a progression through a KL grading scale. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the progression through the KL grading scale compared to the baseline progression through the KL grading scale. In some embodiments, the improvement is a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade. In some embodiments, the improvement is a prevention of the progression through the KL grading scale.
- the improvement is assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
- the improvement a decrease in the rate of progression through the KL grading scale, relative to the baseline rate of progression through the KL grading scale, by 0.1 KL grades per year, 0.25 KL grades per year, 0.5 KL grades per year, 1 KL grade per year, 1.5 KL grades per year, or 2 KL grades per year.
- efficacy of the therapeutically effective dose of the compound of Formula I is measured by an inhibition of progression of a patient’s Kellgren-Lawrence (KL) grade, or an improvement of a patient’s KL grade as compared to a patient’s baseline KL grade as assessed prior to administering to the joint a therapeutically effective dose of the compound of Formula I over a period of time.
- KL Kellgren-Lawrence
- a therapeutically effective dose of the compound of Formula I to the joint of a patient diagnosed with osteoarthritis inhibits
- progression of a patient ’s KL grade from KL grade 1 to 2, or from KL grade 2 to 3, or from KL grade 3 to 4 as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
- a therapeutically effective dose of the compound of Formula I to the joint of a patient diagnosed with osteoarthritis improves or reverses a patient’s KL grade by one KL grade, by two KL grades, by three KL grades, by four KL grades as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
- the compound of Formula I is formulated into one or more pharmaceutical compositions.
- Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that are used pharmaceutically.
- a summary of pharmaceutical compositions described herein is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference for such disclosure.
- the compound of Formula I is synthesized according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. Specific and analogous reactants may also be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., may be contacted for more details). Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses ( e.g ., those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the present disclosure is P. H. Stahl & C. G.
- the study is a randomized, double-blind, placebo-controlled single ascending dose study to evaluate safety, tolerability, and pharmacokinetics of the compound of Formula I, in patients diagnosed with painful femoro-tibial osteoarthritis.
- the study consists of 2 parts: the first part (Part A) is a single ascending dose study, whereas the second part (Part B) is a single dose study at a dose that has been determined to be safe and tolerable in first part of the study (see FIG. 1).
- Part A 48 subjects were randomly allocated to receive the compound of Formula I (between 0.1 mg to 4 mg) or placebo in 3 : 1 randomization by dose level (cohort), whereas in Part B, 30 subjects were randomly allocated to receive the compound of Formula I (4 mg dose) or placebo in a 2: 1 randomization (see FIG. 12 and FIG. 13).
- the primary objective was to establish the safety and tolerability of the compound of Formula I given as a single intra-articular injection into the femoro-tibial joint of patients with osteoarthritis as evaluated by the incidence of serious and non-serious adverse events within a 12 week timeframe.
- Plasma concentration of the compound of Formula I over 24 hrs following a single intra-articular injection was monitored. Primary endpoints were safety and tolerability. Secondary and exploratory endpoints included plasma pharmacokinetics, synovitis as measured by MRI, pain, and SASP factors in synovial fluid and plasma. The change from baseline to Week 12 of the weekly mean of the average daily pain intensity score as obtained using the 11 -point numerical rating scale, as measured from 0-10, where 0 represents no pain and 10 represents worst pain imaginable. In addition, the change from baseline to Week 12 for the Western Ontario and McMaster Universities (WOMAC) index total score and the pain and function subscales using the 5-point Likert scale were also measured.
- WOMAC Western Ontario and McMaster Universities
- Part B The change from baseline to Week 4 of selected senescence- associated secretory phenotype (SASP) factors in plasma samples and in synovial fluid aspirates in patients receiving a single intra-articular injection of the compound of Formula I versus those receiving placebo, were measured. Primary endpoints were safety and tolerability. Secondary endpoints included changes in the levels of SASP factors present in synovial fluid and plasma, and pain. Synovial fluid samples were obtained at baseline and four weeks post-treatment.
- SASP senescence- associated secretory phenotype
- Patient Inclusion Criteria Patients must be > 40 and ⁇ 85 years of age. Patients using non-steroidal anti-inflammatory agent must be on a consistent regimen, dose, and medication for at least 8 weeks prior to receiving treatment.
- Patient Exclusion Criteria Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the health care professional constitutes a risk or contraindication for treatment. Also excluded are any patients with clinically significant co-existing conditions of the cardiovascular, renal, gastrointestinal, respiratory, nervous, metabolic, or hematologic/ immune systems, as judged by their health care professional. Further, any patients with a history of diabetes mellitus according to the American Diabetes Association criteria or patients previously diagnosed by a qualified physician as having diabetes (American Diabetes Association Standards of Medical Care in Diabetes 2016) are also excluded from treatment. Any patients with a history of cardiac rhythm disturbances, abnormal ECG intervals, or use of medications known to impact ECG intervals are excluded.
- Exclusion criteria for the first part only: Patients with an effusion at the screening visit which, in the opinion of the health care professional following examination and discussions with the patient, requires drainage for symptom relief are excluded from treatment.
- patients who have received intra-articular treatment with steroids or hyaluronic acid derivatives within the last 16 weeks prior to screening are excluded from treatment. Also excluded are those patients who use, or have used in the 8 weeks prior to screening, opioid analgesics (with exception of mild opioid analgesics). Patients who have had regenerative joint procedures on any joint including, but not limited to, platelet-rich plasma injections, mesenchymal stem cell transplantation, autologous chondrocyte transplantation, or mosaicplasty are also excluded from treatment.
- patients with a current or history of other joint diseases such as joint dysplasia, crystal -induced arthropathy (such as gout, or calcium pyrophosphate deposition disease evidenced by clinical and/or radiographic means), aseptic osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause, are also excluded from treatment.
- joint dysplasia crystal -induced arthropathy (such as gout, or calcium pyrophosphate deposition disease evidenced by clinical and/or radiographic means)
- aseptic osteonecrosis acromegaly
- Paget's disease Ehlers-Danlos Syndrome
- Gaucher's disease Gaucher's disease
- Stickler's syndrome Joint infection
- hemophilia hemochromatosis
- neuropathic arthropathy of any cause are also
- any active known or suspected systemic autoimmune disease except for vitiligo, residual auto-immune hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment for two years, conditions not expected to recur in the absence of an external trigger
- any history of a systemic inflammatory arthritis such as psoriatic, rheumatoid, ankylosing spondylitis or reactive arthritis will prevent a patient from receiving treatment.
- patients diagnosed presently and symptomatic with fibromyalgia based on American College of Radiology (ACR) Criteria are also excluded from treatment.
- patients with a BMI > 40 kg/m2, or whose size exceed the limits of the of the MRI equipment (coil and gantry) will be excluded from treatment.
- NRS Numerical Rating Scale
- WOMAC-A In Part A, evaluation of pain by WOMAC-A mean item score (0-4 scale) measured at 12 weeks demonstrated a dose-dependent and clinically meaningful reduction. The range of mean baseline values was between 1.80 to 2.36. Part A WOMAC-A pain data are shown in FIG. 3, FIG. 4 and FIG. 9B. Part A NRS pain data are shown in FIG. 5, FIG. 6 and FIG. 9A. The data indicate that a single dose of the compound of Formula I decreased pain, and that the decrease was durable, dose-dependent, and substantial.
- SASP Factors In Part A, an insufficient number of matched samples were collected due to a lack of withdrawable synovial fluid from patients. Therefore, an analysis of change in SASP from factors from baseline to 12 weeks was not performed. In Part B, 19 biomarkers were analyzed across 20 matched pair samples (FIG. 10). Trends in changes to the levels of particular SASP factors present in synovial fluid (treatment versus placebo) were consistent with senescent cell removal. The SASP factors that changed their prevalence in synovial fluid after the compound of Formula I treatment were MMP-10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, and VEGF-C.
- a second clinical study will be conducted to assess effects of the compound of Formula I on moderate to severe painful knee osteoarthritis (OA).
- This Phase 2 study builds on the favorable clinical responses, pharmacokinetic (PK) and safety results obtained in Example 1, and assesses the efficacy, safety, and tolerability of a single-dose IA administration of the compound of Formula I in symptomatic knee OA.
- PK pharmacokinetic
- the study includes a randomized, double-blind, placebo-controlled, single-dose, parallel-group study to assess the efficacy, safety, and tolerability of a single-dose intra-articular (IA) administration of the compound of Formula I in patients with moderate to severe painful knee OA (for example, established femoro-tibial OA).
- IA intra-articular
- the study includes approximately 180 total patients > 40 and ⁇ 85 years of age with moderate to severe painful knee OA. Approximately 45 patients are randomly (1 : 1 : 1 : 1) included in each of the following 4 groups:
- the 4 groups are enrolled concurrently. Approximately 40 patients per group complete a Week 12 visit, assuming a 10% dropout rate. A Week 24 visit is also included. Either the compound of Formula I or placebo is administered as a single 8 mL IA injection on Day 1 of Week 0.
- the endpoint analyses include changes from baseline to Weeks 12 and 24 in the patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo (see FIG. 11).
- ACR Criteria based on clinical and radiologic ACR criteria for at least 6 months) and who have baseline pain with a mean of > 4 and ⁇ 9 on the 11 -point (0-10) average daily pain NRS for at least five of seven days during the Screening period.
- norepinephrine reuptake inhibitors such as Cymbalta ® (duloxetine), tramadol, or acetaminophen, provided that they have been taking a stable dose and regimen of medication for at least 4 weeks prior to Screening.
- Patients with type 2 diabetes mellitus can be included as long as they are under adequate control (screening hemoglobin Ale ⁇ 8.0) and have no evidence or history of diabetic neuropathy.
- BMI body mass index
- musculoskeletal involvement except for vitiligo, residual autoimmune hypothyroidism requiring only hormone replacement, psoriasis not requiring systemic treatment for 2 years, or conditions not expected to recur in the absence of an external trigger
- a systemic inflammatory arthritis such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or spondylitis, or reactive arthritis.
- anticoagulants e.g., low molecular weight heparin or warfarin
- factor Xa inhibitors e.g., Eliquis®/apixaban
- P2Y 12 inhibitors e.g., Plavix®/clopidogrel or ticagrelor
- Patients with a history of traumatic knee injury to the target knee including, but not limited to, patients with meniscal root tear, within 2 years of study entry.
- knee OA Patients with secondary arthritis that involves the target knee or would confound assessments of knee OA, e.g., joint dysplasia, chronic or recurrent crystal-induced arthritis (gout, calcium pyrophosphate deposition disease, podagra, etc.), aseptic osteonecrosis, acromegaly, Paget’s disease, Ehlers-Danlos syndrome, Gaucher’s disease, Stickler’s syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause.
- joint dysplasia chronic or recurrent crystal-induced arthritis (gout, calcium pyrophosphate deposition disease, podagra, etc.)
- aseptic osteonecrosis acromegaly
- Paget’s disease Ehlers-Danlos syndrome
- Gaucher’s disease Gaucher’s disease
- Stickler’s syndrome Joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause.
- Female patients who are pregnant, lactating, or of childbearing potential who do not agree to use highly effective methods of birth control e.g., progesterone-only hormonal contraception, double barrier, or intrauterine device
- highly effective methods of birth control e.g., progesterone-only hormonal contraception, double barrier, or intrauterine device
- Postmenopausal females > 45 years old and without menses for more than 1 year
- surgically sterilized females are exempt from these requirements.
- a primary objective in this study is to evaluate the effect of IA administration of the compound of Formula I on the change from baseline to Week 12 of pain in the target knee.
- An endpoint for this objective is change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale (WOMAC-A) score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo.
- Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their WOMAC-A scores that are greater than in the placebo group.
- each treatment with the compound of Formula I is expected to decrease knee pain within 12 weeks.
- An additional objective is to evaluate the effect of IA administration of the compound of Formula I on the change from baseline to Week 12 in physical function.
- An endpoint for this objective is change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale (WOMAC-C) score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo.
- Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their WOMAC-C scores that are greater than in the placebo group.
- each treatment with the compound of Formula I is expected to increase knee function within 12 weeks.
- An additional objective is to evaluate the effect of IA administration of the compound of Formula I on the change from baseline to Week 12 in pain reported by patients daily over the 12-week study period.
- An endpoint for this objective is change from baseline to Week 12 of the weekly mean of the average daily pain intensity scores on the 11 -point numeric rating scale (NRS) in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo.
- Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their NRS that are greater than in the placebo group.
- each treatment with the compound of Formula I is expected to decrease knee pain within 12 weeks.
- An additional objective is to evaluate the effect of IA administration of the compound of Formula I on the duration of symptom improvement (pain and function) following IA administration of the compound of Formula I out to 24 weeks. Endpoints for this objective include change from baseline (over the entire 24-week period, including both the primary study period and the 12-week follow-up period) out to Week 24 for the WOMAC-A, NRS, and WOMAC-C scores in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in each of their WOMAC-A, NRS, and WOMAC-C scores that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to decrease knee pain and increase knee function until at least 24 weeks after the treatment.
- An additional objective is to evaluate the safety and tolerability of single-dose IA administration of the compound of Formula I. Endpoints for this objective include incidence of adverse events (AEs) as well as change from baseline through Weeks 12 and 24 in vital signs and selected laboratory safety parameters (as deemed clinically appropriate) in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo.
- An AE for purposes of this study is any untoward medical occurrence associated with the treatment whether or not it is considered treatment related. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have a low incidence of AEs, and not to show serious adverse affects on their vital signs throughout the study period. Thus, each treatment with the compound of Formula I is expected to be safe and tolerable.
- An additional objective is to explore the effects of single-dose IA administration of the compound of Formula I on the change from baseline in patient reported assessment of their osteoarthritis at the time of inquiry. Endpoints for this objective include change from baseline to Week 12 and to Week 24 in Patient Global Assessment score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their Patient Global Assessment scores that are greater than in the placebo group at Weeks 12 and 24. Thus, each treatment with the compound of Formula I is expected to improve osteoarthritis within 12 weeks and until at least 24 weeks after the treatment.
- An additional objective is to explore the effects of single-dose IA administration of the compound of Formula I on the change from baseline in patient reported impression of how their osteoarthritis has changed over the course of the study. Endpoints for this objective include change from baseline to Week 12 and to Week 24 in Patient Global Impression of Change score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their reported impressions that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to improve a patient’s impression of how the patient’s osteoarthritis changes within 12 weeks and until at least 24 weeks after the treatment.
- An additional objective is to explore the effects of single-dose IA administration of the compound of Formula I on soluble biomarkers and imaging biomarkers of joint degeneration and repair.
- An endpoint for this objective includes change from baseline out to Week 24 in serum/plasma and urine biomarkers of synovium, cartilage, and bone degeneration.
- Another endpoint for this objective is change from baseline to Week 24 in magnetic resonance imaging-based markers of joint structure.
- Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have beneficial changes in serum/plasma and urine biomarkers of synovium, cartilage, and bone degeneration, and in magnetic resonance imaging-based markers of joint structure, that are greater than in the placebo group at Weeks 12 and 24.
- each treatment with the compound of Formula I is expected to improve soluble biomarker levels within and until at least 24 weeks after the treatment. Further, each treatment with the compound of Formula I is expected to improve imaging biomarkers of joint degeneration and repair within 12 weeks and until at least 24 weeks after the treatment.
- results are expected to indicate that the compound of Formula I is effective, safe, and tolerable in patients with moderate to severe painful knee OA.
- a single AI dose of the compound of Formula I at, for example, 0.5, 2, or 4 mg, is expected to be effective for achieving each of these results.
- Each of these results are expected within 12 weeks of treatment, and are expected to last until at least 24 weeks after treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed herein are methods of treating a patient diagnosed with osteoarthritis in a joint by administering therapeutically effective doses of compositions that decrease synovitis or pain in the joint.
Description
METHOD OF TREATING THE OSTEOARTHRITIC JOINT
CROSS-REFERENCE
[0001] This application claims the benefit of U.S. Provisional Application No. 62/862,672, filed June 17, 2019, and U.S. Provisional Application No. 62/931,719, filed November 6, 2019, which applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Osteoarthritis is a progressive joint disease in which the cartilage between bones in the joint breaks down causing joint pain and stiffness. Osteoarthritis is characterized by breakdown of the cartilage, deterioration of tendons and ligaments, and various degrees of inflammation in the synovium (the joint lining).
SUMMARY OF THE INVENTION
[0003] Disclosed herein are methods of treating a patient diagnosed with osteoarthritis in a joint comprising administering to the joint a therapeutically effective dose of a compound of Formula I, or a pharmaceutically acceptable salt thereof:
wherein the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound of Formula I results in a decrease in synovitis in the joint. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle. In some embodiments, the compound of Formula I is administered intra-articularly to the joint. In some embodiments, the joint is a fern oro-tibial joint. In some embodiments, the joint is a hip. In some embodiments, the joint is spine, shoulder, ankle, wrist, or finger joint. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered as a single dose. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months. In some embodiments, the
therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years. In some embodiments, the patient is > 40 years of age. In some embodiments, the patient is < 85 years of age. In some embodiments, the patient is > 40 and < 85 years of age. In some embodiments, a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I. In some embodiments, the baseline measurement is a baseline pain level. In some embodiments, the baseline pain level is assessed using a pain assessment protocol. In some embodiments, the pain assessment protocol is an 11- point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC) Index pain sub scale. In some embodiments, the baseline measurement is a baseline functionality level. In some embodiments, the baseline functionality level is assessed by WOMAC Index functional subscale. In some embodiments, the baseline measurement is a baseline radiological categorization. In some embodiments, the baseline radiological categorization is a Kellgren- Lawrence grade. In some embodiments, the joint is the femoro-tibial joint.In some
embodiments, the baseline measurement is a baseline synovitis level. In some embodiments, the baseline synovitis level of the patient is assessed using an 1 lpoint MRI score. In some embodiments, the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 1 point as measured by the 1 lpoint MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 4 points, at least 5 points, at least 8 points, at least 9 points, at least 10 points, wherein the decrease is between 1-4 points, between 4-8 points, between 8-10 points, between 10-13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of between 1-4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the baseline measurement is a baseline synovial fluid level. In some embodiments, the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRI. In some embodiments, the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level. In some embodiments, the decrease in synovial fluid in the joint is measured 24
weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the therapeutically effective dose of the compound of Formula I further results in a decrease in pain in the joint as compared to the baseline pain level. In some embodiments, the decrease in pain in the joint is measured 12 weeks or measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11- point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40-50% as measured by the 11-point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale. In some embodiments, the increase in functionality of the joint is measured 12 weeks or 24 weeks after the compound of Formula I is administered to the patient. In some
embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points. In some embodiments, the baseline measurement is a
baseline biomarker level. In some embodiments, the baseline biomarker levels are measured from the patient’s synovial fluid. In some embodiments, the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level. In some embodiments, the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease. In some embodiments, the biomarker comprises MMP- 10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, measured 12 weeks, or measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression. In some embodiments, the biomarker comprises a cytokine or chemokine such as CCL20, CCL19, IL-10, or IL-6. In some embodiments, the biomarker comprises IL-6. In some embodiments, the biomarker comprises a growth factor or adhesion molecule such as ICAM-1 or VEGF-C. In some embodiments, the biomarker comprises a protease or protease inhibitor such as MMP-3, MMP-10, MMP-12, MMP-13, or A2M. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, or more. In some embodiments, the therapeutically effective dose is in at least 8.5 ml, at least 9 mL, at least 10 mL, at least 11 mL, at least 12 mL, or more, of vehicle. In some embodiments, the therapeutically effective dose results in an improved joint architecture measurement. In some embodiments, a baseline joint architecture measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I, and wherein the improved joint architecture measurement comprises an improvement compared to the baseline joint architecture measurement. In some embodiments, the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or X-ray device. In some embodiments, the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement. In some embodiments, the joint architecture measurement comprises a cartilage thickness measurement. In some embodiments, the baseline joint architecture measurement comprises a baseline cartilage thickness measurement. In some embodiments, the cartilage thickness measurement and the baseline cartilage thickness measurement are measured using X- ray or MRI. In some embodiments, the cartilage thickness measurement comprises a joint space width (JSW) measurement. In some embodiments, the baseline cartilage thickness measurement
comprises a baseline JSW measurement. In some embodiments, the improvement comprises an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01,
0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 mm, or more. In some embodiments, the cartilage thickness measurement comprises a joint space narrowing (JSN) measurement. In some embodiments, the baseline cartilage thickness measurement comprises a baseline JSN measurement. In some embodiments, the improvement comprises reversing, stopping or decreasing the JSN measurement relative to the baseline JSN measurement. In some embodiments, the joint architecture measurement comprises a subchondral bone surface area measurement. In some embodiments, the baseline joint architecture measurement comprises a baseline subchondral bone surface area measurement. In some embodiments, the improvement comprises a 50 Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the subchondral bone surface area measurement relative to the baseline subchondral bone surface area measurement. In some embodiments, the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI. In some embodiments, the joint architecture measurement comprises a Kellgren-Lawrence (KL) grade. In some embodiments, the baseline joint architecture measurement comprises a baseline KL grade. In some embodiments, the improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more. In some embodiments, the joint architecture measurement comprises a progression through a KL grading scale. In some embodiments, the baseline joint architecture measurement comprises a baseline progression through the KL grading scale. In some embodiments, the improvement comprises a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade, or comprises preventing the progression through the KL grading scale, as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
[0004] Disclosed herein are methods of treating a patient diagnosed with osteoarthritis in a joint comprising administering to the joint a therapeutically effective dose of a compound of Formula I, or a pharmaceutically acceptable salt thereof:
(Formula I)
wherein the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound of Formula I results in a decrease in pain in the joint. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, or more. In some embodiments, the therapeutically effective dose is in at least 8.5 ml, at least 9 mL, at least 10 mL, at least 11 mL, at least 12 mL, or more, of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle. In some embodiments, the compound of Formula I is administered intra-articularly to the joint. In some embodiments, the joint is a femoro-tibial joint. In some embodiments, the joint is a hip. In some embodiments, the joint is spine, shoulder, ankle, wrist, or finger joint. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered as a single dose. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years. In some embodiments, the patient is > 40 years of age. In some embodiments, the patient is < 85 years of age. In some embodiments, the patient is > 40 and < 85 years of age. In some embodiments, a baseline measurement is obtained from the patient prior to
administering to the joint a therapeutically effective dose of the compound of Formula I. In some embodiments, the baseline measurement is a baseline pain level. In some embodiments, the joint pain and/or baseline pain level is assessed using a pain assessment protocol. In some embodiments, the pain assessment protocol is an 11 -point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC) Index pain subscale. In some
embodiments, the baseline measurement is a baseline functionality level. In some embodiments, the baseline functionality level is assessed by WOMAC Index functional subscale. In some embodiments, the baseline measurement is a baseline radiological categorization. In some embodiments, the baseline radiological categorization is a Kellgren-Lawrence grade. In some embodiments, the joint is the fern oro-tibial joint. In some embodiments, the baseline
measurement is a baseline synovial fluid level. In some embodiments, the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRI. In some embodiments, the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level. In some embodiments, the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain in the joint is measured 12 weeks, or 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40- 50% as measured by the 11 -point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the
WOMAC Index functionality subscale. In some embodiments, the increase in functionality of the joint is measured 12 weeks or 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points. In some embodiments, the baseline measurement is a baseline biomarker level. In some embodiments, the baseline biomarker levels are measured from the patient’s synovial fluid. In some embodiments, the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level.
In some embodiments, the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease. In some embodiments, the biomarker comprises MMP-10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, or measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression. In some embodiments, the biomarker comprises a cytokine or chemokine such as CCL20, CCL19, IL-10, or IL-6. In some embodiments, the biomarker comprises IL-6. In some embodiments, the biomarker comprises a growth factor or adhesion molecule such as ICAM-1 or VEGF-C. In some embodiments, the biomarker comprises a protease or protease inhibitor such as MMP-3, MMP-10, MMP-12, MMP-13, or A2M. In some embodiments, the therapeutically effective dose results in an improved joint architecture measurement. In some embodiments, a baseline joint architecture measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I, and wherein the improved joint architecture measurement comprises an improvement compared to the baseline joint architecture measurement. In some embodiments, the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or X-ray device. In some embodiments, the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement. In some embodiments, the joint architecture measurement comprises a cartilage thickness measurement. In some embodiments, the baseline
joint architecture measurement comprises a baseline cartilage thickness measurement. In some embodiments, the cartilage thickness measurement and the baseline cartilage thickness measurement are measured using X-ray or MRI. In some embodiments, the cartilage thickness measurement comprises a joint space width (JSW) measurement. In some embodiments, the baseline cartilage thickness measurement comprises a baseline JSW measurement. In some embodiments, the improvement comprises an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10,
0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2,
1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 mm, or more. In some embodiments, the cartilage thickness measurement comprises a joint space narrowing (JSN) measurement. In some embodiments, the baseline cartilage thickness measurement comprises a baseline JSN measurement. In some embodiments, the improvement comprises reversing, stopping or decreasing the JSN
measurement relative to the baseline JSN measurement. In some embodiments, the joint architecture measurement comprises a subchondral bone surface area measurement. In some embodiments, the baseline joint architecture measurement comprises a baseline subchondral bone surface area measurement. In some embodiments, the improvement comprises a 50 Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the subchondral bone surface area measurement relative to the baseline subchondral bone surface area measurement. In some embodiments, the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI. In some embodiments, the joint architecture measurement comprises a Kellgren-Lawrence (KL) grade. In some embodiments, the baseline joint architecture measurement comprises a baseline KL grade. In some embodiments, the
improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more. In some embodiments, the joint architecture measurement comprises a progression through a KL grading scale. In some embodiments, the baseline joint architecture measurement comprises a baseline progression through the KL grading scale. In some embodiments, the improvement comprises a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade, or comprises preventing the progression through the KL grading scale, as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years
or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
BRIEF DESCRIPTION OF THE DRAWINGS
[0005] The novel features of the disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative
embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
[0006] FIG. 1 illustrates a Phase I clinical trial single ascending dose study.
[0007] FIG. 2 illustrates that no serious adverse events were observed in a Phase I clinical trial single ascending dose study.
[0008] FIG. 3 illustrates a dose dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) sub scores.
[0009] FIG. 4 illustrates a grouped dosage dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by WOMAC subscores.
[0010] FIG. 5 illustrates a dose dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by a numerical rating scale (NRS).
[0011] FIG. 6 illustrates a grouped dosage dependent effect of the compound of Formula I in decreasing osteoarthritis pain as assessed by an NRS.
[0012] FIG. 7 illustrates a dose dependent effect of the compound of Formula I in improving physical function in subjects with osteoarthritis, as assessed by WOMAC subscores.
[0013] FIG. 8 illustrates a grouped dosage dependent effect of the compound of Formula I in improving physical function in subjects with osteoarthritis, as assessed by WOMAC subscores.
[0014] FIG. 9A illustrates a beneficial effect on pain, as assessed by an NRS, of a single dose of the compound of Formula I relative to placebo.
[0015] FIG. 9B illustrates a beneficial effect on pain, as assessed by WOMAC subscores, of a single dose of the compound of Formula I relative to placebo.
[0016] FIG. 9C illustrates a beneficial effect on physical function, as assessed by WOMAC subscores, of a single dose of the compound of Formula I relative to placebo.
[0017] FIG. 10 illustrates effects of the compound of Formula I relative to placebo on synovial fluid biomarkers levels.
[0018] FIG. 11 illustrates a design for a Phase II clinical trial.
[0019] FIG. 12 illustrates patient demographics in a clinical study.
[0020] FIG. 13 illustrates baseline patient characteristics in a clinical study.
[0021] FIG. 14 illustrates beneficial effects of the compound of Formula I in subjects with osteoarthritis, as assessed by Patient Global Impression of Change (PGIC) scores.
[0022] FIG. 15 illustrates effects of the compound of Formula I on pain and physical function in subjects with osteoarthritis, as assessed by WOMAC subscores.
INCORPORATION BY REFERENCE
[0023] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
PET ATT, ED DESCRIPTION OF THE INVENTION
[0024] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the embodiments provided may be practiced without these details. Unless the context requires otherwise, throughout the specification and claims which follow, the word“comprise” and variations thereof, such as,“comprises” and“comprising” are to be construed in an open, inclusive sense, that is, as“including, but not limited to.” As used in this specification and the appended claims, the singular forms“a,”“an,” and“the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term“or” is generally employed in its sense including“and/or” unless the content clearly dictates otherwise. Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.
[0025] Osteoarthritis is a degenerative joint disease characterized by fibrillation of the cartilage at sites of high mechanical stress, bone sclerosis, and thickening of the synovium and the joint capsule. Fibrillation is a local surface disorganization involving splitting of the superficial layers of the cartilage. The early splitting is tangential with the cartilage surface, following the axes of the predominant collagen bundles. Collagen within the cartilage becomes disorganized, and proteoglycans are lost from the cartilage surface. In the absence of protective and lubricating effects of proteoglycans in a joint, collagen fibers become susceptible to degradation, and mechanical destruction ensues. Predisposing risk factors for developing osteoarthritis include increasing age, obesity, previous joint injury, overuse of the joint, weak thigh muscles, and genetics. It is a common cause of chronic disability in the elderly.
Symptoms of osteoarthritis include sore or stiff joints, particularly the hips, knees, and lower back, after inactivity or overuse; stiffness after resting that goes away after movement; and pain
that is worse after activity or toward the end of the day. Chronic inflammation is thought to be the main age-related factor that contributes to osteoarthritis.
[0026] Senescent cells accumulate in tissues and organs of individuals as they age and are found at sites of age-related pathologies, including osteoarthritic joints. Senescent cells are believed important to inhibiting proliferation of dysfunctional or damaged cells and particularly to constraining development of malignancy (see, e.g., Campisi, Curr. Opin. Genet. Dev. 21 : 107-12 (2011); Campisi, Trends Cell Biol. 11 : S27-31 (2001); Prieur et al., Curr. Opin. Cell Biol.
20: 150-55 (2008)); nevertheless, cellular senescence is a molecular mechanism that drives age- associated osteoarthritis and also osteoarthritis caused by joint trauma.
[0027] A senolytic agent is an agent that selectively (preferentially or to a greater degree) destroys, kills, removes, or facilitates selective destruction of senescent cells over non-senescent cells of the same cell type. A senolytic agent is used in an amount and for a time sufficient that selectively kills senescent cells but is insufficient to cause the death of a non-senescent cell.
[0028] Senolytic agents, such as the compound of Formula I, as shown below, prevent (i.e., reduces the likelihood of occurrence), reduces or inhibits loss or erosion of proteoglycan layers in a joint, reduces inflammation in the affected joint, and promotes (i.e., stimulates, enhances, induces) production of collagen (e.g., type 2 collagen). Removal of senescent cells causes a reduction in the amount (i.e., level) of inflammatory cytokines such as, for example, IL-6, produced in a joint and inflammation is reduced. Methods are provided herein for treating osteoarthritis, for selectively killing senescent cells in an osteoarthritic joint of a subject, and/or inducing, for example, collagen (such as Type 2 collagen) production in the joint of a subject in need thereof by administering at least one senolytic agent (which may be combined with at least one pharmaceutically acceptable excipient to form a pharmaceutical composition) to the subject. A senolytic agent also may be used for decreasing (inhibiting, reducing) production of, for example, metalloproteinase 13 (MMP-13), which degrades collagen in a joint, and for restoring proteoglycan layer or inhibiting loss and/or degradation of the proteoglycan layer. Treatment with the senolytic agent thereby also prevents (i.e., reduces likelihood of occurrence of), inhibits, or decreases erosion, or slows (i.e., decreases rate) erosion of the bone. In addition, the methods comprising administering a senolytic agent can reduce joint pain and are therefore useful for pain management of osteoarthritic joints.
[0029] Disclosed herein are methods of treating a patient diagnosed with osteoarthritis in a joint comprising administering to the joint a therapeutically effective dose of a compound of Formula I, or a pharmaceutically acceptable salt thereof:
(Formula I)
wherein the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound results in a decrease in synovitis in the joint. The compound of Formula I is shown in the structure above and is also known as 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(l- methylethoxy)phenyl]-lH-imidazol-l-yl]carbonyl]-2-piperazinone. The present disclosure further contemplates that therapeutically effective doses of cytotoxins, or cytostatic agents of which the compound of Formula I is an example, may be efficacious in treating an osteoarthritic joint as described herein.
Therapeutically effective dose of the compound of Formula I
[0030] In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 12 mL of vehicle.
In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose
of the compound of Formula I is at least 2 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula
I is 2 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 9 mL of vehicle. In some embodiments, the
therapeutically effective dose of the compound of Formula I is 2 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in
I I mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 2 mg in 16 mL of vehicle.
[0031] In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 7 mL of vehicle. In some
embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 3 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 3 mg in 16 mL of vehicle.
[0032] In some embodiments, the therapeutically effective dose of the compound of Formula I
is at least 4 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 10 mL of vehicle. In some embodiments, the
therapeutically effective dose of the compound of Formula I is 4 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 4 mg in 16 mL of vehicle.
[0033] In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 6 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 3 mL
of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 6 mg in 16 mL of vehicle.
[0034] In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 12 mL of vehicle. In some
embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is at least 8 mg in at least 16 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 1 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 2 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 3 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 4 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 5 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 6 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 7 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 8 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 9 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 10 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 11 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 12 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 13 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 14 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 15 mL of vehicle. In some embodiments, the therapeutically effective dose of the compound of Formula I is 8 mg in 16 mL of vehicle.
Administration
[0035] In some embodiments, the compound of Formula I is administered locally to the joint. In some embodiments, the compound of Formula I is administered intra-articularly to the joint.
In some embodiments, the joint is a fern oro-tibial joint. In some embodiments, the joint is a hip. In some embodiments, the joint is spine, shoulder, ankle, wrist, or finger joint. In some embodiments, the joint is the spine. In some embodiments, the joint is the shoulder. In some embodiments, the joint is the ankle. In some embodiments, the joint is the wrist. In some
embodiments, the joint is the finger.
[0036] In some embodiments, the therapeutically effective dose of the compound of Formula I is administered as a single dose. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months. In some embodiments, the
therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year. In some embodiments, the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years.
[0037] In some embodiments, the joint has senescent cells. In some embodiments, the senescent cells are senescent chondrocytes or senescent epithelial cells, or senescent synoviocytes. In some embodiments, the senescent cells are senescent chondrocytes. In some embodiments, the senescent cells are senescent epithelial cells. In some embodiments, the senescent cells are senescent synoviocytes.
[0038] Senescent cells may be detected by morphology (as viewed by microscopy, for example); production of senescence associated markers such as, for example,
senescence-associated b-galactosidase (SA-P-gal), rΐό11^43, p21, PAI-1, or any one or more SASP factors ( e.g IL-6, MMP3).The presence of the senescent cell-associated polypeptide pl6 can be determined by standard immunochemistry, such as immunoblotting analysis. Expression of pl6 mRNA in a cell can be measured by a variety of techniques including quantitative PCR.
Patient
[0039] As used herein the term“individual,”“patient,” or“subject” refers to individuals diagnosed with, suspected of being afflicted with, or at-risk of developing at least one disease for which the described compositions and method are useful for treating. In certain
embodiments, the individual is a mammal. In certain embodiments, the mammal is a human.
[0040] In some embodiments, the patient is > 40 years of age. In some embodiments, the patient is > 45 years of age. In some embodiments, the patient is > 50 years of age. In some embodiments, the patient is > 55 years of age. In some embodiments, the patient is > 60 years of age. In some embodiments, the patient is < 85 years of age. In some embodiments, the patient is
< 80 years of age. In some embodiments, the patient is < 75 years of age. In some embodiments, the patient is < 70 years of age. In some embodiments, the patient is < 75 years of age. In some embodiments, the patient is > 40 and less than < 85 years of age. In some embodiments, the patient is > 45 and less than < 80 years of age. In some embodiments, the patient is > 50 and less than < 75 years of age. In some embodiments, the patient is > 55 and less than < 70 years of age.
[0041] In some embodiments, a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
[0042] In some embodiments, the baseline measurement is a baseline pain level. In some embodiments, the baseline pain level is assessed using a pain assessment protocol. In some embodiments, the pain assessment protocol is an 11 -point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC) Index pain subscale.
[0043] In some embodiments, the pain assessment protocol is the 11 -point Numeric Rating Scale (NRS). In some embodiments, the 11 -point Numeric Rating Scale (NRS) comprises asking the patient to rate their pain on a scale from 0 to 10 during, for example but not limited to, a 24 hour period, in which 0 is no pain, and 10 represents the worst possible pain. In some embodiments, the baseline pain level of the patient is a mean of > 3 and < 9 points on the 11- point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 4 and < 9 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 5 and < 9 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 3 and < 8 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 4 and < 8 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 5 and < 8 points on the 11- point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 3 and < 7 points on the 11 -point NRS In some embodiments, the baseline pain level of the patient is a mean of > 4 and < 7 points on the 11 -point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 5 and < 7 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 4 and < 5 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 5 and < 6 points on the 11- point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 6 and < 7 points on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 7 and < 8 points on the 11 -point NRS. In some embodiments, the baseline pain level of the patient is a mean of > 8 and < 9 points on the 11 -point NRS. As used herein the term “about” refers to an amount that is near the stated amount by 10% or less. In some embodiments,
the baseline pain level of the patient is a mean of about 4 on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of about 5 on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of about 6 on the 11 -point NRS. In some embodiments, the baseline pain level of the patient is a mean of about 7 on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of about 8 on the 11-point NRS. In some embodiments, the baseline pain level of the patient is a mean of about 9 on the 11 -point NRS.
[0044] In some embodiments, the pain assessment protocol is the WOMAC pain subscale. In some embodiments, the WOMAC Index pain subscale comprises a set of questionnaires in which a health professional evaluates the condition of the patient. In some embodiments, the questionnaire contains 5 questions pertaining to the amount of pain that the patient feels during walking, using stairs, in bed, sitting, and standing. Each question is scored on a scale of 0 to 4 which correspond to: none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores are summed up, with a total possible score of 0-20 for the pain subscale. In some embodiments, the baseline pain level of the patient is > 6 on the WOMAC pain subscale. In some
embodiments, the baseline pain level of the patient is > 6 and less than <_17 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than < 16 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than <_15 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than <_14 on the WOMAC pain subscale. In some
embodiments, the baseline pain level of the patient is > 6 and less than <_13 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than < 12 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than <_11 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is > 6 and less than <_10 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 6. In some embodiments, the baseline pain level of the patient is 7 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 8 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 9 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 10 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 11 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 12 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 13 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 14 on the WOMAC pain subscale. In some embodiments, the
baseline pain level of the patient is 15 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 16 on the WOMAC pain subscale. In some embodiments, the baseline pain level of the patient is 17 on the WOMAC pain sub scale. In some embodiments, the baseline pain level of the patient is 18 on the WOMAC pain sub scale. In some
embodiments, the baseline pain level of the patient is 19 on the WOMAC pain subscale.
[0045] In some embodiments, the baseline measurement is a baseline functionality level. In some embodiments, the baseline functionality level is assessed by WOMAC Index functionality subscale. In some embodiments, the baseline functionality level is assessed by WOMAC Index functional subscale. In some embodiments, the WOMAC Index functional subscale comprises a set of questionnaires in which a health professional evaluates the condition of the patient. In some embodiments, the questionnaire contains 17 questions such as, for example: the degree of difficulty with performing the following: A. Descending stairs, B. Ascending stairs, C. Rising from sitting, D. Standing, E. Bending to floor, F. Walking on a flat surface, G. Getting in or out of a car, H. Going shopping, I. Putting on socks/stockings, J. Rising from bed, K. Taking off socks/stockings, L. Lying in bed, M. Getting in/out of the bath, N. Sitting, O. Getting on/off the toilet, P. Heavy domestic duties (such as mowing the lawn, lifting heavy grocery bags), Q. Light domestic duties (such as tidying a room, dusting, or cooking).
[0046] Each question is scored on a scale of 0 to 4 which correspond to: none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores are summed up, with a total possible score of 0-68 for the WOMAC functional subscale. In some embodiments, the baseline functionality level of the patient is > 17 and < 68. In some embodiments, the baseline functionality level of the patient is > 18 and < 68. In some embodiments, the baseline functionality level of the patient is > 19 and < 68. In some embodiments, the baseline functionality level of the patient is > 20 and < 68. In some embodiments, the baseline functionality level of the patient is > 21 and < 68. In some embodiments, the baseline functionality level of the patient is > 22 and < 68. In some embodiments, the baseline functionality level of the patient is > 23 and < 68. In some embodiments, the baseline functionality level of the patient is > 24 and < 68. In some embodiments, the baseline functionality level of the patient is > 25 and < 68. In some embodiments, the baseline functionality level of the patient is > 26 and < 68. In some embodiments, the baseline functionality level of the patient is > 27 and < 68. In some embodiments, the baseline functionality level of the patient is > 28 and < 68. In some embodiments, the baseline functionality level of the patient is > 29 and < 68. In some embodiments, the baseline functionality level of the patient is > 30 and < 68. In some embodiments, the baseline functionality level of the patient is > 31 and < 68. In some
embodiments, the baseline functionality level of the patient is > 32 and < 68. In some embodiments, the baseline functionality level of the patient is > 33 and < 68. In some embodiments, the baseline functionality level of the patient is > 34 and < 68. In some embodiments, the baseline functionality level of the patient is > 35 and < 68. In some embodiments, the baseline functionality level of the patient is > 36 and < 68. In some embodiments, the baseline functionality level of the patient is > 37 and < 68. In some embodiments, the baseline functionality level of the patient is > 38 and < 68. In some embodiments, the baseline functionality level of the patient is > 39 and < 68. In some embodiments, the baseline functionality level of the patient is > 40 and < 68. In some embodiments, the baseline functionality level of the patient is > 41 and < 68. In some embodiments, the baseline functionality level of the patient is > 42 and < 68. In some embodiments, the baseline functionality level of the patient is > 43 and < 68. In some embodiments, the baseline functionality level of the patient is > 44 and < 68. In some embodiments, the baseline functionality level of the patient is > 45 and < 68. In some embodiments, the baseline functionality level of the patient is > 46 and < 68. In some embodiments, the baseline functionality level of the patient is > 47 and < 68. In some embodiments, the baseline functionality level of the patient is > 48 and < 68. In some embodiments, the baseline functionality level of the patient is > 49 and < 68. In some embodiments, the baseline functionality level of the patient is > 30 and < 68. In some embodiments, the baseline functionality level of the patient is > 31 and < 68. In some embodiments, the baseline functionality level of the patient is > 32 and < 68. In some embodiments, the baseline functionality level of the patient is > 33 and < 68. In some embodiments, the baseline functionality level of the patient is > 34 and < 68. In some embodiments, the baseline functionality level of the patient is > 35 and < 68. In some embodiments, the baseline functionality level of the patient is > 36 and < 68. In some embodiments, the baseline functionality level of the patient is > 37 and < 68. In some embodiments, the baseline functionality level of the patient is > 38 and < 68. In some embodiments, the baseline functionality level of the patient is > 39 and < 68. In some embodiments, the baseline functionality level of the patient is > 50 and < 68. In some embodiments, the baseline functionality level of the patient is > 51 and < 68. In some embodiments, the baseline functionality level of the patient is > 52 and < 68. In some embodiments, the baseline functionality level of the patient is > 53 and < 68. In some embodiments, the baseline functionality level of the patient is > 54 and < 68. In some embodiments, the baseline functionality level of the patient is > 55 and < 68. In some
embodiments, the baseline functionality level of the patient is > 56 and < 68. In some embodiments, the baseline functionality level of the patient is > 57 and < 68. In some embodiments, the baseline functionality level of the patient is > 58 and < 68. In some embodiments, the baseline functionality level of the patient is > 59 and < 68. In some embodiments, the baseline functionality level of the patient is > 60 and < 68.
[0047] In some embodiments, the baseline measurement is a baseline stiffness level. In some embodiments, the baseline stiffness level is assessed by WOMAC Index stiffness subscale. In some embodiments, the WOMAC Index stiffness subscale comprises a set of questionnaires in which a health professional evaluates the condition of the patient. In some embodiments, the questionnaire contains 2 questions, such as, for example: How severe is your stiffness after first awakening in the morning? How severe is your stiffness after sitting, lying, or resting later in the day? Each question is scored on a scale of 0 to 4 which correspond to: none (0), mild (1), moderate (2), severe (3), and extreme (4). The scores are summed up, with a total possible score of 0-8 for the WOMAC stiffness subscale. In some embodiments, the baseline stiffness level of the patient is > 1 and < 8. In some embodiments, the baseline stiffness level of the patient is > 1 and < 7. In some embodiments, the baseline stiffness level of the patient is > 1 and < 6. In some embodiments, the baseline stiffness level of the patient is > 1 and < 5. In some embodiments, the baseline stiffness level of the patient is > 1 and < 4. In some embodiments, the baseline stiffness level of the patient is > 1 and < 3. In some embodiments, the baseline stiffness level of the patient is 1. In some embodiments, the baseline stiffness level of the patient is 2. In some embodiments, the baseline stiffness level of the patient is 3. In some embodiments, the baseline stiffness level of the patient is 4. In some embodiments, the baseline stiffness level of the patient is 5. In some embodiments, the baseline stiffness level of the patient is 6. In some embodiments, the baseline stiffness level of the patient is 7. In some embodiments, the baseline stiffness level of the patient is 8.
[0048] In some embodiments, the baseline measurement is a baseline radiological
categorization. In some embodiments, the baseline radiological categorization is a Kellgren- Lawrence grade. The Kellgren-Lawrence grading system is a radiological classification system for assessing severity of osteoarthritis. The grading system categorizes osteoarthritis severity according to the following grades: grade 0 - no radiographic features of OA are present, grade 1- doubtful joint space narrowing (JSN) and possible osteophytic lipping, grade 2 - definite osteophytes and possible JSN on anteroposterior weight-bearing radiograph, grade 3 - multiple osteophytes, definite JSN, sclerosis, possible bony deformity, grade 4 - large osteophytes, marked JSN, severe sclerosis and definite bony deformity. In some embodiments, the baseline
radiological categorization of the patient is 1 through 4 on the Kellgren-Lawrence grading system. In some embodiments, the baseline radiological categorization of the patient is 1 on the Kellgren-Lawrence grading system. In some embodiments, the baseline radiological categorization of the patient is 2 on the Kellgren-Lawrence grading system. In some
embodiments, the baseline radiological categorization of the patient is 3 on the Kellgren- Lawrence grading system. In some embodiments, the baseline radiological categorization of the patient is 4 on the Kellgren-Lawrence grading system. In some embodiments, the baseline radiological categorization is of the fern oro-tibial joint.
[0049] In some embodiments, the baseline measurement is a baseline synovitis level. In some embodiments, the baseline synovitis level is assessed using an 11 point MRI score based on Guermazi et al. [assessment of synovitis with contrast-enhanced MRI using a while-joint semiquantitiative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study.” Ann Rheum Dis 2011;70:805-811. In the 11 point MRI reading, 9 anatomical sites as outlined in Table 1 are evaluated for synovitis. If present, Baker’s cysts or loose bodies, are scored in addition to the 9 anatomical locations. Synovitis comprises an inflammation of the synovial membrane and is characterized on MRI by thickening and enhancement after administration of intravenous contrast agent. Each site as outlined in Table 1 is scored based on the maximal thickness in any slice at each site as follows: grade 0 if <2 mm, grade 1 if 2-4 mm and grade 2 if >4 mm (as shown in Table 2) with a maximal score of 22. The scores are summed to calculate a synovitis level (as shown in Table 3).
Table 1. Locations for 11 point MRI score
Table 2. Synovial Thickness Scoring
Table 3. Summed Score Categories
[0050] In some embodiments, the baseline synovitis level of the patient is at least 7 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 8 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 9 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 10 as measured by the 11 point MRI score.
In some embodiments, the baseline synovitis level of the patient is at least 11 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least
12 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 13 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 14 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 15 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is at least 16 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is > 7 and < 18 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is > 8 and < 17 as measured by the 11 point MRI score. In some embodiments, the baseline synovitis level of the patient is > 8 and < 16 as measured by the 11 point MRI score.
[0051] In some embodiments, the baseline measurement is a baseline joint architecture measurement. In some embodiments, joint architecture refers to bone structure, cartilage structure, joint space width (JSW), or joint space narrowing (JSN), in the joint. In some embodiments, the baseline joint architecture measurement is a baseline cartilage thickness measurement, a baseline subchondral bone surface area measurement, a baseline Kellgren- Lawrence (KL) grade, or a baseline progression through a KL grading scale. In some
embodiments, the baseline joint architecture measurement is baseline bone, tendon, or meniscus measurement. In some embodiments, the baseline joint architecture measurement is measured using MRI, ultrasound, computed tomography, or an X-ray device. In some embodiments, the joint of the baseline joint architecture measurement is a knee. In some embodiments, the knee is the patient’s left knee. In some embodiments, the knee is the patient’s right knee.
[0052] In some embodiments, the baseline joint architecture measurement is a baseline cartilage thickness measurement. In some embodiments, the baseline cartilage thickness measurement is measured using X-ray or MRI. In some embodiments, the baseline cartilage thickness measurement is a baseline joint space width (JSW) measurement or a baseline joint space narrowing (JSN) measurement.
[0053] In some embodiments, the baseline cartilage thickness measurement is a baseline joint space width (JSW) measurement. In some embodiments, the baseline JSW measurement is a baseline medial JSW measurement. In some embodiments, the baseline JSW measurement is a baseline lateral JSW measurement. In some embodiments, the baseline JSW is a baseline minimum JSW. In some embodiments, the baseline minimum JSW is the shortest visible distance between the femoral condyle and the tibial plateau.
[0054] In some embodiments, the baseline JSW measurement is 2 mm. In some embodiments, the baseline JSW measurement is 2.5 mm. In some embodiments, the baseline JSW
measurement is 3 mm. In some embodiments, the baseline JSW measurement is 3.5 mm. In some embodiments, the baseline JSW measurement is 4 mm. In some embodiments, the baseline JSW measurement is 4.5 mm. In some embodiments, the baseline JSW measurement is 5 mm. In some embodiments, the baseline JSW measurement is 5.5 mm. In some embodiments, the baseline JSW measurement is 6 mm. In some embodiments, the baseline JSW measurement is 6.5 mm. In some embodiments, the baseline JSW measurement is 7 mm.
[0055] In some embodiments, the baseline cartilage thickness measurement is a baseline joint space narrowing (JSN) measurement. When JSN occurs, cartilage in the joint may wear away, and the existing cartilage may be prevented from keeping bones of the joint a normal distance apart. In some embodiments, the baseline JSN measurement is a baseline change in JSW. In some embodiments, the baseline JSW measurement is measured based on longitudinal changes in a minimum JSW measurement. In some embodiments, the baseline change in JSW of the baseline JSN measurement is 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12,
0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4,
1.5, 1.6, 1.7, 1.8, 1.9, or 2.0 mm, or more. In some embodiments, the baseline JSN measurement is a baseline change in JSW over time. In some embodiments, the time of the baseline change in JSW over time is 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years. For example, the baseline JSN measurement may be 0.02 to 0.05 mm per year.
[0056] In some embodiments, the baseline joint architecture measurement is a baseline subchondral bone surface area measurement. In some embodiments, the baseline subchondral bone surface area measurement is measured using X-ray or MRI. In some embodiments, the baseline subchondral bone surface area measurement is a baseline bone density. In some embodiments, the baseline bone density is 200 Hounsfield Units (HU), 250 HU, 300 HU, 350
HU, 400 HU, 450 HU, 500 HU, 550 HU, 600 HU, 650 HU, 700 HU, 750 HU, or 800 HU. In some embodiments, the baseline subchondral bone surface area measurement is a baseline number of cystic areas. In some embodiments, the baseline subchondral bone surface area measurement is a baseline number of cystic areas is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more. In some embodiments, the cystic areas comprise low-density bone areas.
[0057] In some embodiments, the baseline joint architecture measurement is a baseline
Kellgren-Lawrence (KL) grade, or a grade using another ordinal scoring system. In some embodiments, the baseline KL grade is 1. In some embodiments, the baseline KL grade is 2. In some embodiments, the baseline KL grade is 3. In some embodiments, the baseline KL grade is
4. In some embodiments, the baseline KL grade is 2 or 3. In some embodiments, the baseline KL grade is 3 or 4. In some embodiments, the baseline KL grade is 2, 3 or 4.
[0058] In some embodiments, the baseline joint architecture measurement is a baseline progression through a KL grading scale. In some embodiments, the baseline progression through the KL grading scale comprises a KL grade increase. In some embodiments, the KL grade increase is 0.5. In some embodiments, the KL grade increase is 1. In some embodiments, the KL grade increase is 2. In some embodiments, the KL grade increase is 3. In some embodiments, the KL grade increase of the baseline progression through the KL grading scale is over time. In some embodiments, time of the KL grade increase is 1 month, 2 months, 3 months, 4 months,
5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years. For example, the baseline progression through a KL grading scale may be a 0.5 grade increase per year.
Efficacy of Therapeutically effective dose of the compound of Formula I
[0059] In some embodiments, efficacy of the therapeutically effective dose of the compound of Formula I is assessed. In some embodiments, a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
[0060] In some embodiments, the baseline measurement is a baseline synovitis level. In some embodiments, the baseline synovitis level is assessed using an 11 point MRI score. In some embodiments, the decrease in synovitis in the joint is measured by the 11-point MRI score.
[0061] In some embodiments, the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 1 point as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
In some embodiments, the decrease in synovitis is by a decrease of at least 4 points, at least 5 points, at least 8 points, at least 9 points, at least 10 points, wherein the decrease is between 1-4 points, between 4-8 points, between 8-10 points, between 10-13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some
embodiments, the decrease in synovitis is by a decrease of between 1-4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
[0062] In some embodiments, the decrease in synovitis is by a decrease of at least 2 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
In some embodiments, the decrease in synovitis is by a decrease of at least 3 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 5 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 6 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 7 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 8 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 9 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 10 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 11 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 12 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 14 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 15 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 16 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 17 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 18 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some embodiments, the decrease in synovitis is by a decrease of at least 19 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient. In some
embodiments, the decrease in synovitis is by a decrease of at least 20 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
[0063] In some embodiments, the decrease in synovitis in the joint is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovitis in the joint is measured 1 year after the compound of Formula I is administered to the patient.
[0064] In some embodiments, the baseline measurement is a baseline synovial fluid level. In some embodiments, the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRF In some embodiments, the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level. In some embodiments, the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
[0065] In some embodiments, the decrease in synovial fluid in the joint is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 10 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in synovial fluid in the joint is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments,
the decrease in synovial fluid in the joint is measured 1 year after the compound of Formula I is administered to the patient.
[0066] In some embodiments, efficacy of the therapeutically effective dose of the compound of Formula I is assessed. In some embodiments, a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
[0067] In some embodiments, the baseline measurement is a pain level. In some embodiments, the therapeutically effective dose of the compound of Formula I further results in a decrease in pain in the joint as compared to the baseline pain level. In some embodiments, the decrease in pain in the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain in the joint is measured 24 weeks after the compound of Formula I is administered to the patient.
[0068] In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 1 point as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 2 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 3 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 4 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 5 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 6 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 7 points as assessed by the 11- point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 8 points as assessed by the 11-point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 9 points as assessed by the 11 -point NRS. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 10 points as assessed by the 11 -point NRS.
[0069] In some embodiments, the decrease in pain in the joint is a change from the baseline
pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 0.5 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 1 point as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 2 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 3 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 4 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 5 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 6 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 7 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 8 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 9 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 10 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 11 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 12 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 13 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 14 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 15 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about
16 points as assessed by the WOMAC Index pain sub scale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 17 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 18 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 19 points as assessed by the WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 20 points as assessed by the WOMAC Index pain sub scale.
[0070] In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40-50% as measured by the 11 -point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 50% as measured by the 11 -point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 40% as measured by the 11 -point NRS or
WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 30% as measured by the 11 -point NRS or
WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 20% as measured by the 11 -point NRS or
WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 10% as measured by the 11 -point NRS or
WOMAC Index pain subscale. In some embodiments, the decrease in pain in the joint is a change from the baseline pain level of about 5% as measured by the 11 -point NRS or WOMAC Index pain subscale. In some embodiments, the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
[0071] In some embodiments, the decrease in pain is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments,
the decrease in pain is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the decrease in pain is measured 1 year after the compound of Formula I is administered to the patient.
[0072] In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 3 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 4 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 5 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 6 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 7 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 8 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 9 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 10 months. In some
embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 11 months. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 1 year. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 2 years. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 3 years. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 4 years. In some embodiments, the decrease the decrease in pain relative to the baseline pain level lasts about 5 years.
[0073] In some embodiments, the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale. In some embodiments, the increase in functionality of the joint is measured 12 weeks after the compound of Formula I is administered to the patient.
In some embodiments, the increase in functionality of the joint is measured 24 weeks after the compound of Formula I is administered to the patient.
[0074] In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at
least seven points, at least eight points, at least nine points, or at least ten points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 0.5 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 1 point. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 2 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 3 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 4 points.
In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 5 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 6 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 7 points.
In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 8 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 9 points. In some embodiments, the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of about 10 points.
[0075] In some embodiments, the increase in functionality of the joint is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the increase in functionality of the joint is measured 1 year after the compound of Formula I is administered to the patient.
[0076] In some embodiments, the baseline measurement is a baseline stiffness level. In some
embodiments, the baseline stiffness level is assessed by WOMAC Index stiffness subscale. In some embodiments, the therapeutically effective dose of the compound of Formula I results in a decrease stiffness in the joint as assessed by WOMAC Index stiffness subscale relative to the baseline stiffness level. In some embodiments, the decrease in stiffness in the joint is a change from the baseline stiffness level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points as assessed by WOMAC Index stiffness subscale. In some embodiments, the decrease in stiffness in the joint is measured 24 weeks, or 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
[0077] In some embodiments, efficacy of the therapeutically effective dose of the compound of Formula I is assessed. In some embodiments, a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula F In some embodiments, the baseline measurement is a baseline biomarker level. In some embodiments, the baseline biomarker levels are measured from the patient’s synovial fluid. In some embodiments, the baseline biomarker levels are measured from the patient’s plasma. In some embodiments, the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level. In some embodiments, the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease. In some embodiments, the modulation of the biomarker levels relative to the baseline biomarker levels is an increase. In some embodiments, the biomarker comprises MMP- 10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C. In some embodiments, the biomarker comprises CXCL10, CCL20, CCL19, CXCL1, CD14, Complement protein C3, GDF15, IL-10, IL-6, fibronectin, ICAM-1, VEGF-C, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M. In some embodiments, the biomarker comprises CCL20, CCL19, IL-10, IL-6, ICAM-1, VEGF-C, MMP-3, MMP-10, MMP-12, MMP-13, or A2M. In some embodiments, the biomarker comprises IL-6. However, the biomarker is not limited to these examples.
[0078] In some embodiments, the biomarker comprises a cytokine or chemokine. In some embodiments, the cytokine or chemokine comprises C-X-C motif chemokine 10 (CXCL10; Perrott et al. Geroscience 2017; Kisand et al. Osteoarthritis Cartilage 2018), Chemokine (C-C motif) ligand 20 (CCL20; Freund et al. Trends Mol Med. 2010; Alaaeddine et al. Inflamm Res. 2015), Chemokine (C-C motif) ligand 19 (CCL19; Carter et al. Genome Biol. 2005; Robinson et al. Nat Rev Rheumatol. 2017), Interleukin 11 (IL-11; Freund et al. Trends Mol Med. 2010; Kokebie et al. Arthritis Res Ther. 2011), S100 calcium-binding protein A8 (S100A8; Ruan et al.
Osteoarthritis Cartilage 2019), chemokine (C-X-C motif) ligand 1 (CXCL1; Freund et al. Trends Mol Med. 2010; Moradi et al. Clin Exp Immunol. 2015), cluster of differentiation 14 (CD 14; Gomez -Aristizabal et al. Arthritis Res Ther. 2019), Interleukin 1 beta (IL-Ib; Freund et al.
Trends Mol Med. 2010; De Bakker et al. Veterinary Record 2017; Fujita et al. Am J Vet Res. 2005), Complement protein C3 (Cardoso et al. Ageing Res Rev. 2018), Growth Differentiation Factor 15 (GDF15; Kim et al. Genes Dev. 2018; Cevidanes et al. Osteoarthritis Cartilage 2014), Granulocyte-macrophage colony-stimulating factor (GM-CSF; Freund et al. Trends Mol Med. 2010; Lee et al. Arthritis Res Ther. 2018), Interleukin 10 (IL-10; Greenhill et al. Arthritis Res Ther. 2014), Chemokine (C-X-C motif) ligand 6 (CXCL6; Freund et al. Trends Mol Med. 2010; Scanzello J Orthop Res. 2017), Interleukin 6 (IL-6; Freund et al. Trends Mol Med. 2010; Guan et al. Discov Med. 2019), Tumor necrosis factor receptor 2 (TNFR2; Freund et al. Trends Mol Med. 2010; Simao et al. Rheumatol Int. 2014), or a combination thereof. In some embodiments, the cytokine or chemokine comprises CXCL10, CCL20, CCL19, CXCL1, CD14, C3, GDF15, IL-10, IL-6, or a combination thereof. In some embodiments, the cytokine or chemokine comprises CCL20, CCL19, IL-10, IL-6, or a combination thereof. In some embodiments, the cytokine or chemokine comprises IL-6. In some embodiments, the cytokine or chemokine is selected from the group consisting of CXCL10, CCL20, CCL19, IL-11, S100A8, CXCL1,
CD 14, IL-Ib, C3, GDF15, GM-CSF, IL-10, CXCL6, IL-6, and TNFR2. In some embodiments, the cytokine or chemokine is selected from the group consisting of CXCL10, CCL20, CCL19, CXCL1, CD14, C3, GDF15, IL-10, and IL-6. In some embodiments, the cytokine or chemokine is selected from the group consisting of CCL20, CCL19, IL-10, and IL-6. In some embodiments, the cytokine or chemokine is IL-6.
[0079] In some embodiments, the biomarker comprises a growth factor or adhesion molecule. In some embodiments, the growth factor or adhesion molecule comprises fibronectin (Scuderi et al. J Bone Joint Surg Am. 2011), intercellular adhesion molecule 1 (ICAM-1; Freund et al.
Trends Mol Med. 2010; Karatay et al. Ann Clin Lab Sci. 2004), vascular endothelial growth factor C (VEGF-C; Paavonen et al. J Rheumatol. 2002; Wauke et al. J Rheumatol. 2002), serpin family F member 1 (SERPINFl; Ritter et al. Arthritis Res Ther. 2014), Pigment epithelium- derived factor (PEDF), or a combination thereof. In some embodiments, the growth factor or adhesion molecule comprises fibronectin, ICAM-1, VEGF-C, or a combination thereof. In some embodiments, the growth factor or adhesion molecule comprises ICAM-1, VEGF-C, or a combination thereof. In some embodiments, the growth factor or adhesion molecule is selected from the group consisting of ICAM-1, VEGF-C, SERPINFl, and PEDF. In some embodiments, the growth factor or adhesion molecule is selected from the group consisting of fibronectin,
ICAM-1, and VEGF-C. In some embodiments, the growth factor or adhesion molecule is selected from the group consisting of ICAM-1 and VEGF-C.
[0080] In some embodiments, the biomarker comprises a protease or a protease inhibitor. In some embodiments, the protease or protease inhibitor comprises matrix metalloproteinase- 1 (MMP-1; Nagase et al. Matrix Suppl. 1992; Freund et al. Trends Mol Med. 2010; Wyatt et al. Osteoarthritis Cartilage 2018), matrix metalloproteinase-3 (MMP-3; Sellers and Murphy Int Rev Connect Tissue Res. 1981; Freund et al. Trends Mol Med. 2010; Cevidanes et al. Osteoarthritis Cartilage 2014), matrix metalloproteinase- 13 (MMP-13; Mitchell et al. J Clin Invest. 1996; Reboul et al. J Clin Invest. 1996; Freund et al. Trends Mol Med. 2010; Ma et al. Connect Tissue Res. 2019), TEMP metallopeptidase inhibitor 1 (TEMPI; Freund et al. Trends Mol Med. 2010; Cevidanes et al. Osteoarthritis Cartilage 2014), A2M (Chou et al. Osteoarthritis Cartilage 2018; Zhao et al. J Cell Biochem. 2015) or a combination thereof. In some embodiments, the protease or protease inhibitor comprises MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TEMP-1, A2M, or a combination thereof. In some embodiments, the protease or protease inhibitor comprises MMP-3, MMP-10, MMP-12, MMP-13, A2M, or a combination thereof. In some embodiments, the protease or protease inhibitor is selected from the group consisting of MMP-1, MMP-3, MMP-13, and TEMPI. In some embodiments, the protease or protease inhibitor is selected from the group consisting of MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TEMP-1, and A2M. In some embodiments, the protease or protease inhibitor is selected from the group consisting of MMP-3, MMP-10, MMP-12, MMP-13, and A2M.
[0081] In some embodiments, the biomarker comprises a cytokine or chemokine, a growth factor or adhesion molecule, or a protease or a protease inhibitor. Examples of cytokines, chemokines, growth factors, adhesion molecules, proteases, and protease inhibitors include but are not limited to those provided above. In some embodiments, the biomarker comprises a biomarker other than a cytokine, chemokine, growth factor, adhesion molecule, protease, or protease inhibitor.
[0082] In some embodiments, the biomarker comprises a cytokine or chemokine, or a growth factor or adhesion molecule. For example, the biomarker may comprise CXCL10, CCL20, CCL19, CXCL1, CD 14, C3, GDF15, IL-10, IL-6, fibronectin, ICAM-1, or VEGF-C. In some embodiments, the biomarker comprises CCL20, CCL19, IL-10, IL-6, ICAM-1, or VEGF-C. In some embodiments, the biomarker comprises IL-6, fibronectin, ICAM-1, or VEGF-C. In some embodiments, the biomarker comprises IL-6, ICAM-1, or VEGF-C.
[0083] In some embodiments, the biomarker comprises a cytokine or chemokine, or a protease or a protease inhibitor. For example, the biomarker may comprise CXCL10, CCL20, CCL19,
CXCL1, CD 14, C3, GDF15, IL-10, IL-6, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M. In some embodiments, the biomarker comprises CCL20, CCL19, IL-10, IL- 6, MMP-3, MMP-10, MMP-12, MMP-13, or A2M. In some embodiments, the biomarker comprises IL-6, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M. In some embodiments, the biomarker comprises IL-6, MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
[0084] In some embodiments, the biomarker comprises a growth factor or adhesion molecule, or a protease or a protease inhibitor. For example, the biomarker may comprise fibronectin, ICAM-1, VEGF-C, MMP-1, MMP-3, MMP-10, MMP-12, MMP-13, TIMP-1, or A2M. In some embodiments, the biomarker comprises ICAM-1, VEGF-C, MMP-3, MMP-10, MMP-12, MMP- 13, or A2M.
[0085] In some embodiments, the level of CCL20 is decreased relative to a baseline CCL20 level. In some embodiments, the level of CCL19 is increased relative to a baseline CCL19 level. In some embodiments, the level of IL-10 is decreased relative to a baseline IL-10 level. In some embodiments, the level of IL-6 is decreased relative to a baseline IL-6 level. In some
embodiments, the level of MMP-3 is increased relative to a baseline MMP-3 level. In some embodiments, the level of MMP-10 is decreased relative to a baseline MMP-10 level. In some embodiments, the level of MMP-12 is decreased relative to a baseline MMP-12 level. In some embodiments, the level of MMP-13 is decreased relative to a baseline MMP-13 level. In some embodiments, the level of A2M is increased relative to a baseline A2M level. In some embodiments, the level of ICAM-1 is increased relative to a baseline ICAM-1 level. In some embodiments, the level of VEGF-C is decreased relative to a baseline VEGF-C level.
[0086] In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, measured 12 weeks, or measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 2 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 6 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 8 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 10 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker
relative to the baseline biomarker level is measured 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 24 weeks after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 6 months after the compound of Formula I is administered to the patient. In some embodiments, the modulation of the biomarker relative to the baseline biomarker level is measured 1 year after the compound of Formula I is administered to the patient.
[0087] In some embodiments, the contemplated treatment methods result in a "much improved" or "very much improved" patient global impression of change (PGIC) for the patient. PGIC, as used herein, is a patient-reported outcome of how a treatment is progressing, and can be used as an indicator of meaningful change in treatments, such as for example, osteoarthritic pain. As used herein, the PGIC is scored on a 5 level scale, ranging from (5): minimally worse; (4): no change; (3): minimally improved; (2) much improved; and (1) very much improved.
[0088] In some embodiments, the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression.
[0089] In some embodiments, the baseline measurement is a joint architecture measurement.
In some embodiments, the therapeutically effective dose of the compound of Formula I further results in an improvement in the joint architecture measurement compared to the baseline joint architecture measurement. In some embodiments, the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement. In some embodiments, the improvement in the joint architecture measurement is measured 24 weeks, or 12 weeks after the compound of Formula I is administered to the patient. In some embodiments, the joint architecture measurement is a cartilage thickness measurement, a subchondral bone surface area measurement, a Kellgren- Lawrence (KL) grade, or a progression through a KL grading scale. In some embodiments, the joint architecture measurement is bone, tendon, or meniscus measurement. In some
embodiments, the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or an X-ray device. In some embodiments, the joint of the joint architecture measurement is a knee. In some embodiments, the knee is the patient’s left knee. In some embodiments, the knee is the patient’s right knee.
[0090] In some embodiments, the baseline joint architecture measurement is a baseline cartilage thickness measurement. In some embodiments, the joint architecture measurement is a cartilage
thickness measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the cartilage thickness measurement compared to the baseline cartilage thickness measurement. In some embodiments, the cartilage thickness measurement is measured using X-ray or MRI.
[0091] In some embodiments, the baseline cartilage thickness measurement is a baseline joint space width (JSW) measurement. In some embodiments, the cartilage thickness measurement is a JSW measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the JSW measurement compared to the baseline JSW measurement. In some embodiments, the JSW measurement is a medial JSW measurement. In some embodiments, the JSW measurement is a lateral JSW measurement. In some
embodiments, the JSW measurement is a minimum JSW. In some embodiments, the JSW is the shortest visible distance between the femoral condyle and the tibial plateau.
[0092] In some embodiments, the improvement is an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1,
1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 mm, or more. For example, the improvement may be an increase in the JSW measurement relative to the baseline JSW measurement of 0.01-2.00 mm, 0.02-1.00 mm, or 0.05-0.50 mm, or 0.10-0.20 mm. In some embodiments, the improvement is an increase in the JSW measurement relative to the baseline JSW measurement of 0.1-0.6 mm. In some embodiments, the increase in the JSW measurement is at least 0.01 mm. In some embodiments, the increase in the JSW measurement is at least 0.05 mm. In some embodiments, the increase in the JSW measurement is at least 0.10 mm. In some embodiments, the increase in the JSW measurement is at least 0.25 mm. In some embodiments, the increase in the JSW measurement is at least 0.50 mm. In some embodiments, the increase in the JSW measurement is at least 1.00 mm. In some embodiments, the increase in the JSW measurement is at least 1.50 mm. In some embodiments, the increase in the JSW measurement is at least 2.00 mm. In some embodiments, the increase in the JSW measurement is at least 2.50 mm.
[0093] In some embodiments, the baseline cartilage thickness measurement is a baseline joint space narrowing (JSN) measurement. In some embodiments, the cartilage thickness
measurement is a JSN measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the JSN measurement compared to the baseline JSN measurement. In some embodiments, the improvement comprises reversing, stopping or decreasing the JSN measurement relative to the baseline JSN measurement.
[0094] In some embodiments, the JSW measurement is measured based on longitudinal changes in a minimum JSW measurement. In some embodiments, the change in JSW of the JSN measurement is 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0 mm, less than a change in a JSW of a baseline JSN measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I decreases JSN by 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2.0 mm, or more. For example, the therapeutically effective dose of the compound of Formula I may decrease JSN by 0.05-2.00 mm, 0.1-0.6 mm, 0.10-1.50 mm, or 0.20-1.00 mm. In some embodiments, the JSN measurement is a change in JSW over time. In some embodiments, the time of the change in JSW over time is 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, or 10 years. For example, the improvement may be a JSN measurement of 0.02 to 0.05 mm per year less than the baseline JSN measurement.
[0095] In some embodiments, the baseline joint architecture measurement is a baseline subchondral bone surface area measurement. In some embodiments, the joint architecture measurement is a subchondral bone surface area measurement. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the subchondral bone surface area measurement compared to the baseline subchondral bone surface area measurement. In some embodiments, the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI.
[0096] In some embodiments, the subchondral bone surface area measurement is a bone density measurement, and the improvement is an increase in the bone density measurement compared to a baseline bone density measurement. In some embodiments, the improvement is a 50
Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the bone density measurement relative to the baseline bone density measurement. In some embodiments, the subchondral bone surface area measurement is a number of cystic areas compared to a baseline number of cystic areas. In some embodiments, the improvement is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, less cystic areas than the baseline number of cystic areas. In some embodiments, the cystic areas comprise low-density bone areas.
[0097] In some embodiments, the baseline joint architecture measurement is a baseline KL grade. In some embodiments, the joint architecture measurement is a Kellgren-Lawrence (KL)
grade. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the KL grade compared to the baseline KL grade. In some embodiments, the improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by half a KL grade. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by one KL grade.
In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by two KL grades. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by three KL grades. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by four KL grades. In some embodiments, the improvement is a decrease in the KL grade relative to the baseline KL grade by 0.5-4 KL grades.
[0098] In some embodiments, the baseline joint architecture measurement is a baseline progression through the KL grading scale. In some embodiments, the joint architecture measurement is a progression through a KL grading scale. In some embodiments, the therapeutically effective dose of the compound of Formula I results in an improvement in the progression through the KL grading scale compared to the baseline progression through the KL grading scale. In some embodiments, the improvement is a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade. In some embodiments, the improvement is a prevention of the progression through the KL grading scale. In some embodiments, the improvement is assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I. In some embodiments, the improvement a decrease in the rate of progression through the KL grading scale, relative to the baseline rate of progression through the KL grading scale, by 0.1 KL grades per year, 0.25 KL grades per year, 0.5 KL grades per year, 1 KL grade per year, 1.5 KL grades per year, or 2 KL grades per year.
[0099] In some embodiments, efficacy of the therapeutically effective dose of the compound of Formula I is measured by an inhibition of progression of a patient’s Kellgren-Lawrence (KL) grade, or an improvement of a patient’s KL grade as compared to a patient’s baseline KL grade as assessed prior to administering to the joint a therapeutically effective dose of the compound
of Formula I over a period of time. In some embodiments, a therapeutically effective dose of the compound of Formula I to the joint of a patient diagnosed with osteoarthritis inhibits
progression of a patient’s KL grade from KL grade 1 to 2, or from KL grade 2 to 3, or from KL grade 3 to 4 as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, 5 years or more after administration of the therapeutically effective dose of the compound of Formula I. In some embodiments, a therapeutically effective dose of the compound of Formula I to the joint of a patient diagnosed with osteoarthritis improves or reverses a patient’s KL grade by one KL grade, by two KL grades, by three KL grades, by four KL grades as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
Pharmaceutical Compositions
[00100] In some embodiments, the compound of Formula I is formulated into one or more pharmaceutical compositions. Pharmaceutical compositions are formulated in a conventional manner using one or more pharmaceutically acceptable inactive ingredients that facilitate processing of the active compounds into preparations that are used pharmaceutically. A summary of pharmaceutical compositions described herein is found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), herein incorporated by reference for such disclosure.
[00101] In general, the compound of Formula I is synthesized according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. Specific and analogous reactants
may also be identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line databases (the American Chemical Society, Washington, D.C., may be contacted for more details). Chemicals that are known but not commercially available in catalogs may be prepared by custom chemical synthesis houses, where many of the standard chemical supply houses ( e.g ., those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the present disclosure is P. H. Stahl & C. G. Wermuth“Handbook of Pharmaceutical Salts,” Verlag Helvetica Chimica Acta, Zurich, 2002. Methods known to one of ordinary skill in the art may be identified through various reference books and databases. Suitable reference books and treatises detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation.
EXAMPLES
[00102] The following illustrative examples are representative of embodiments of compositions and methods described herein and are not meant to be limiting in any way.
Example 1: Clinical Study
[00103] The following describes a clinical study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of a senolytic in patients diagnosed with painful osteoarthritis of the knee.
[00104] The study is a randomized, double-blind, placebo-controlled single ascending dose study to evaluate safety, tolerability, and pharmacokinetics of the compound of Formula I, in patients diagnosed with painful femoro-tibial osteoarthritis. The study consists of 2 parts: the first part (Part A) is a single ascending dose study, whereas the second part (Part B) is a single dose study at a dose that has been determined to be safe and tolerable in first part of the study (see FIG. 1).
[00105] In Part A, 48 subjects were randomly allocated to receive the compound of Formula I (between 0.1 mg to 4 mg) or placebo in 3 : 1 randomization by dose level (cohort), whereas in Part B, 30 subjects were randomly allocated to receive the compound of Formula I (4 mg dose) or placebo in a 2: 1 randomization (see FIG. 12 and FIG. 13).
[00106] The primary objective was to establish the safety and tolerability of the compound of Formula I given as a single intra-articular injection into the femoro-tibial joint of
patients with osteoarthritis as evaluated by the incidence of serious and non-serious adverse events within a 12 week timeframe.
[00107] For Part A: Plasma concentration of the compound of Formula I over 24 hrs following a single intra-articular injection was monitored. Primary endpoints were safety and tolerability. Secondary and exploratory endpoints included plasma pharmacokinetics, synovitis as measured by MRI, pain, and SASP factors in synovial fluid and plasma. The change from baseline to Week 12 of the weekly mean of the average daily pain intensity score as obtained using the 11 -point numerical rating scale, as measured from 0-10, where 0 represents no pain and 10 represents worst pain imaginable. In addition, the change from baseline to Week 12 for the Western Ontario and McMaster Universities (WOMAC) index total score and the pain and function subscales using the 5-point Likert scale were also measured.
[00108] For Part B: The change from baseline to Week 4 of selected senescence- associated secretory phenotype (SASP) factors in plasma samples and in synovial fluid aspirates in patients receiving a single intra-articular injection of the compound of Formula I versus those receiving placebo, were measured. Primary endpoints were safety and tolerability. Secondary endpoints included changes in the levels of SASP factors present in synovial fluid and plasma, and pain. Synovial fluid samples were obtained at baseline and four weeks post-treatment.
Further, the change from baseline to Week 4 for the WOMAC index pain subscale using as derived from the Knee injury and Osteoarthritis Outcome Score (KOOS) were also measured. Finally, patient plasma concentration of the compound of Formula I following a single intra- articular injection was measured within 24 hours of treatment.
[00109] Patient Inclusion Criteria: Patients must be > 40 and < 85 years of age. Patients using non-steroidal anti-inflammatory agent must be on a consistent regimen, dose, and medication for at least 8 weeks prior to receiving treatment.
1. For the first part of the study only: Ambulatory persons with osteoarthritis of the knee and baseline pain with a mean of > 4 and < 9 points on the 24-hour mean pain score (on the 11 -point Numeric Rating Scale) for at least five of the seven days during the screening period.
2. For the second part of the study only: Ambulatory persons with painful osteoarthritis of the knee for at least six months. Patients being studies in this second part with OA must have Kellgren-Lawrence (K-L) scores 1 through 4 in the target knee. Patients must also have a baseline pain >6 on the WOMAC Index pain subscale as derived from the KOOS.
[00110] Patient Exclusion Criteria: Any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the health
care professional constitutes a risk or contraindication for treatment. Also excluded are any patients with clinically significant co-existing conditions of the cardiovascular, renal, gastrointestinal, respiratory, nervous, metabolic, or hematologic/ immune systems, as judged by their health care professional. Further, any patients with a history of diabetes mellitus according to the American Diabetes Association criteria or patients previously diagnosed by a qualified physician as having diabetes (American Diabetes Association Standards of Medical Care in Diabetes 2016) are also excluded from treatment. Any patients with a history of cardiac rhythm disturbances, abnormal ECG intervals, or use of medications known to impact ECG intervals are excluded. Patients who have undergone diagnostic arthroscopy of the target knee in the previous six months and those patients who have undergone arthroscopic surgery in the last two years prior to the screening visit (including microfracture and menisectomy) on the target knee are both also excluded from treatment. Finally, any patient anticipated to have arthroscopic surgery on either knee at any time or a history of previous total or partial knee arthroplasty in either knee are excluded from treatment.
[00111] Exclusion criteria for the first part only: Patients with an effusion at the screening visit which, in the opinion of the health care professional following examination and discussions with the patient, requires drainage for symptom relief are excluded from treatment.
[00112] Also, patients who have received intra-articular treatment with steroids or hyaluronic acid derivatives within the last 16 weeks prior to screening are excluded from treatment. Also excluded are those patients who use, or have used in the 8 weeks prior to screening, opioid analgesics (with exception of mild opioid analgesics). Patients who have had regenerative joint procedures on any joint including, but not limited to, platelet-rich plasma injections, mesenchymal stem cell transplantation, autologous chondrocyte transplantation, or mosaicplasty are also excluded from treatment. Further, patients with a current or history of other joint diseases such as joint dysplasia, crystal -induced arthropathy (such as gout, or calcium pyrophosphate deposition disease evidenced by clinical and/or radiographic means), aseptic osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause, are also excluded from treatment.
[00113] Any active known or suspected systemic autoimmune disease (except for vitiligo, residual auto-immune hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment for two years, conditions not expected to recur in the absence of an external trigger) or any history of a systemic inflammatory arthritis such as psoriatic, rheumatoid, ankylosing spondylitis or reactive arthritis will prevent a patient from receiving
treatment. Further, patients diagnosed presently and symptomatic with fibromyalgia based on American College of Radiology (ACR) Criteria are also excluded from treatment. Finally, patients with a BMI > 40 kg/m2, or whose size exceed the limits of the of the MRI equipment (coil and gantry) will be excluded from treatment.
Results
[00114] Safety Tolerability and PK In Part A, the compound of Formula I was well tolerated up to the maximum administered dose of 4 mg (See FIG. 2). There were no serious adverse events and no patients discontinued because of an adverse event. There were no dose- dependent adverse events or clinical laboratory findings. The majority (66%) of adverse events were mild. In Part B, the compound of Formula I was well tolerated at the 4 mg dose. There were no serious adverse events and no patients discontinued because of an adverse event. The majority (75%) of adverse events were mild and there were no relevant clinical laboratory findings. The compound of Formula I demonstrated dose-proportional plasma pharmacokinetics. Model-based estimates suggested that doses at or above 1 mg may be pharmacologically active. This informed the low dose (0.1, 0.2, and 0.4 mg) and high dose (1, 2, and 4 mg) groupings for analyses.
[00115] Pain Measures. Numerical Rating Scale (NRS): In Part A, evaluation of pain by NRS (0-10 point scale) measured at 12 weeks demonstrated a dose-dependent and clinically meaningful reduction. The range of mean baseline values was between 5.90 to 6.76.
Table 4. Pain Measure as Assessed by Numerical Rating Scale
CFBL=change from baseline; Pbo-Adj=placebo adjusted; low doses=0.1, 0.2, and 0.4 mg; high doses=l, 2, and 4 mg; Tx=treated
WOMAC-A: In Part A, evaluation of pain by WOMAC-A mean item score (0-4 scale) measured at 12 weeks demonstrated a dose-dependent and clinically meaningful reduction. The range of
mean baseline values was between 1.80 to 2.36. Part A WOMAC-A pain data are shown in FIG. 3, FIG. 4 and FIG. 9B. Part A NRS pain data are shown in FIG. 5, FIG. 6 and FIG. 9A. The data indicate that a single dose of the compound of Formula I decreased pain, and that the decrease was durable, dose-dependent, and substantial.
Table 5. Pain Measure as Assessed by WOMAC-A
CFBL=change from baseline; Pbo-Adj=placebo adjusted; low doses=0.1, 0.2, and 0.4 mg; high doses=l, 2, and 4 mg; Tx=treated
[00116] In Part B, pain, as measured by WOMAC-A mean item score measured at 4 weeks, showed a numerical reduction that was not statistically different from placebo (FIG. 15).
[00117] Other Measures. Evaluation of function by WOMAC-C mean item score (0-4 scale) demonstrated a dose-dependent and clinically meaningful improvement in patients in the high-dose group. Part A WOMAC-C physical function data are shown in FIG. 7, FIG. 8 and FIG. 9C. The data indicate durable, dose-dependent, and substantial improved effects of a single dose of the compound of Formula I on physical function. There were no observed changes in stiffness as measured by WOMAC-B. Evaluation of Patient Global Impression of Change (PGIC) with treatment demonstrated a higher proportion of patients being“much improved” or “very much improved” versus placebo (FIG. 14).
[00118] Exploratory Measures. Synovial Inflammation by MRI: Evaluation of synovial inflammation by MRI showed a variable response across the dose groups. The two lowest doses showed no significant changes. The two intermediate doses showed significant increases (0.4 mg = +1.80, p < 0.01 and 1 mg = +3.69, p < 0.01), whereas the two highest doses showed significant decreases in synovial inflammation (2 mg = -1.18, p < 0.01 and 4 mg = -2.49, p < 0.01).
[00119] SASP Factors: In Part A, an insufficient number of matched samples were collected due to a lack of withdrawable synovial fluid from patients. Therefore, an analysis of
change in SASP from factors from baseline to 12 weeks was not performed. In Part B, 19 biomarkers were analyzed across 20 matched pair samples (FIG. 10). Trends in changes to the levels of particular SASP factors present in synovial fluid (treatment versus placebo) were consistent with senescent cell removal. The SASP factors that changed their prevalence in synovial fluid after the compound of Formula I treatment were MMP-10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, and VEGF-C.
Example 2: Phase 2 Trial
[00120] A second clinical study will be conducted to assess effects of the compound of Formula I on moderate to severe painful knee osteoarthritis (OA). This Phase 2 study builds on the favorable clinical responses, pharmacokinetic (PK) and safety results obtained in Example 1, and assesses the efficacy, safety, and tolerability of a single-dose IA administration of the compound of Formula I in symptomatic knee OA.
[00121] The study includes a randomized, double-blind, placebo-controlled, single-dose, parallel-group study to assess the efficacy, safety, and tolerability of a single-dose intra-articular (IA) administration of the compound of Formula I in patients with moderate to severe painful knee OA (for example, established femoro-tibial OA).
[00122] The study includes approximately 180 total patients > 40 and < 85 years of age with moderate to severe painful knee OA. Approximately 45 patients are randomly (1 : 1 : 1 : 1) included in each of the following 4 groups:
Group 1 : Placebo
Group 2: 0.5 mg of the compound of Formula I
Group 3: 2.0 mg of the compound of Formula I
Group 4: 4.0 mg of the compound of Formula I
[00123] The 4 groups are enrolled concurrently. Approximately 40 patients per group complete a Week 12 visit, assuming a 10% dropout rate. A Week 24 visit is also included. Either the compound of Formula I or placebo is administered as a single 8 mL IA injection on Day 1 of Week 0. The endpoint analyses include changes from baseline to Weeks 12 and 24 in the patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo (see FIG. 11).
[00124] Inclusion Criteria: each patient satisfies the following criteria:
1. Patients who are ambulatory with a diagnosis of OA of the knee, as defined by the
American College of Rheumatology (ACR) Criteria (based on clinical and radiologic ACR criteria for at least 6 months) and who have baseline pain with a mean of > 4 and <
9 on the 11 -point (0-10) average daily pain NRS for at least five of seven days during the Screening period.
2. Patients with a KL grade of 1-4 based on central reading of a weight-bearing radiograph of target knee.
3. Patients aged > 40 and < 85 years.
4. Patients are permitted but not required to use an oral NSAID, serotonin and
norepinephrine reuptake inhibitors (SNRIs) such as Cymbalta® (duloxetine), tramadol, or acetaminophen, provided that they have been taking a stable dose and regimen of medication for at least 4 weeks prior to Screening.
5. Patients with type 2 diabetes mellitus can be included as long as they are under adequate control (screening hemoglobin Ale < 8.0) and have no evidence or history of diabetic neuropathy.
6. Patients who have the capacity to give informed consent and who are willing and able to comply with all study-related procedures and assessments. Patients who do not have the legal capacity or medical competency to give written informed consent are ineligible for this study; consent via legally authorized representative is not accepted.
[00125] Exclusion Criteria: Patients are ineligible if they meet any of the following criteria:
1. Patients with any condition, including laboratory or imaging findings and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator or the Medical Monitor constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation or prevent the patient from fully participating in all aspects of the study.
2. Patients with a body mass index (BMI) > 40 kg/m2 or a body habitus that precludes the MRI.
3. Patients with clinically significant co-existing conditions of the cardiovascular, renal, gastrointestinal, respiratory, nervous (e.g., neuropathy), metabolic, hematologic, or immune system.
4. Patients with fibromyalgia based on ACR criteria.
5. Patients with any active, known, or suspected systemic autoimmune disease with
musculoskeletal involvement (except for vitiligo, residual autoimmune hypothyroidism requiring only hormone replacement, psoriasis not requiring systemic treatment for 2 years, or conditions not expected to recur in the absence of an external trigger) or any
history of a systemic inflammatory arthritis, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or spondylitis, or reactive arthritis.
Patients who have received IA treatment in the target knee with steroids or hyaluronic acid derivatives within the last 16 weeks prior to Screening, or with extended-release corticosteroid (e.g., Zilretta®) within the last 20 weeks prior to Screening.
Patients who are using a topical NSAID or topical analgesics on the target knee.
Patients who are receiving anticoagulants (e.g., low molecular weight heparin or warfarin), factor Xa inhibitors (e.g., Eliquis®/apixaban), or P2Y 12 inhibitors (e.g., Plavix®/clopidogrel or ticagrelor).
Patients who are receiving chronic oral corticosteroids.
Patients who have used opioid analgesics, marijuana or marijuana-derived products (e.g., cannabidiol), and topical capsaicin on the target knee within 8 weeks prior to Screening and at all times during the study.
Patients with a history of traumatic knee injury to the target knee, including, but not limited to, patients with meniscal root tear, within 2 years of study entry.
Patients who have undergone diagnostic arthroscopy to the target knee in the previous 6 months.
Patients who have undergone arthroscopic surgery (including microfracture and meniscectomy) on the target knee in the last 2 years prior to the Screening visit or are anticipated to have arthroscopic surgery on either knee at any time during the study period.
Patients with a history of previous total or partial knee arthroplasty.
Patients with an effusion at the Screening visit, which, in the opinion of the Investigator following examination and discussions with the patient, requires drainage for symptom relief.
Patients who have had regenerative joint procedures on any joint, including, but not limited to, platelet-rich plasma injections, stem cell transplantation, autologous chondrocyte transplantation, or mosaicplasty.
Patients with abnormal alanine aminotransferase or aspartate aminotransferase > 2 c upper limit of normal (ULN) at Screening.
Patients with bilirubin > 2 x ULN at Screening.
Patients with renal dysfunction as defined by a glomerular filtration rate < 30
mL/min/1.73 m2 by laboratory testing (Chronic Kidney Disease Epidemiology
Collaboration method).
Patients with active or untreated hepatitis B or C or any history of human
immunodeficiency virus infection at Screening.
Patients with any known active infections, including suspicion of IA infection and/or predisposition to infections due to immune system compromise.
Patients with a history of malignancy within 5 years and/or current evidence of active malignancy, except basal cell carcinoma, squamous cell carcinoma of the skin, and completely excised cervical intraepithelial neoplasia.
Patients with a history of drug or alcohol dependence within the last 3 years.
Patients with secondary arthritis that involves the target knee or would confound assessments of knee OA, e.g., joint dysplasia, chronic or recurrent crystal-induced arthritis (gout, calcium pyrophosphate deposition disease, podagra, etc.), aseptic osteonecrosis, acromegaly, Paget’s disease, Ehlers-Danlos syndrome, Gaucher’s disease, Stickler’s syndrome, joint infection, hemophilia, hemochromatosis, or neuropathic arthropathy of any cause.
Patients with radiographic (plain X-ray or MRI) evidence of disease that would impact the ability of the study to meet its primary or secondary objectives; examples include the following:
o Patients with a history of osteonecrosis or who are deemed to have or have risk factors for rapid progression of OA, including sub-chondral insufficiency fracture or spontaneous osteonecrosis of the knee
o Patients with recent fractures (stress, pathologic, or traumatic) defined by the presence of a visible fracture line
o Patients with cystic lesion 0.5 c the femoral or tibial subchondral plate o Patients with a history of pigmented villonodular synovitis
Patients who previously received treatment in study of the compound of Formula I. Patients who have received another investigational drug or investigational vaccine within the last 3 months prior to Screening.
Patients who are participating in or are planning to participate concurrently in another investigational drug or vaccine study.
Female patients who are pregnant, lactating, or of childbearing potential who do not agree to use highly effective methods of birth control (e.g., progesterone-only hormonal contraception, double barrier, or intrauterine device) for 3 months following the treatment. Postmenopausal females (> 45 years old and without menses for more than 1 year) and surgically sterilized females are exempt from these requirements.
30. Male patients who do not agree to use a highly effective method of contraception for 3 months following the treatment, if sexually active with a female partner of childbearing potential.
Results
[00126] A primary objective in this study is to evaluate the effect of IA administration of the compound of Formula I on the change from baseline to Week 12 of pain in the target knee. An endpoint for this objective is change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index pain subscale (WOMAC-A) score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their WOMAC-A scores that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to decrease knee pain within 12 weeks.
[00127] An additional objective is to evaluate the effect of IA administration of the compound of Formula I on the change from baseline to Week 12 in physical function. An endpoint for this objective is change from baseline to Week 12 of the Western Ontario and McMaster Universities Osteoarthritis Index function subscale (WOMAC-C) score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their WOMAC-C scores that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to increase knee function within 12 weeks.
[00128] An additional objective is to evaluate the effect of IA administration of the compound of Formula I on the change from baseline to Week 12 in pain reported by patients daily over the 12-week study period. An endpoint for this objective is change from baseline to Week 12 of the weekly mean of the average daily pain intensity scores on the 11 -point numeric rating scale (NRS) in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their NRS that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to decrease knee pain within 12 weeks.
[00129] An additional objective is to evaluate the effect of IA administration of the compound of Formula I on the duration of symptom improvement (pain and function) following IA administration of the compound of Formula I out to 24 weeks. Endpoints for this objective include change from baseline (over the entire 24-week period, including both the primary study
period and the 12-week follow-up period) out to Week 24 for the WOMAC-A, NRS, and WOMAC-C scores in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in each of their WOMAC-A, NRS, and WOMAC-C scores that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to decrease knee pain and increase knee function until at least 24 weeks after the treatment.
[00130] An additional objective is to evaluate the safety and tolerability of single-dose IA administration of the compound of Formula I. Endpoints for this objective include incidence of adverse events (AEs) as well as change from baseline through Weeks 12 and 24 in vital signs and selected laboratory safety parameters (as deemed clinically appropriate) in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. An AE for purposes of this study is any untoward medical occurrence associated with the treatment whether or not it is considered treatment related. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have a low incidence of AEs, and not to show serious adverse affects on their vital signs throughout the study period. Thus, each treatment with the compound of Formula I is expected to be safe and tolerable.
[00131] An additional objective is to explore the effects of single-dose IA administration of the compound of Formula I on the change from baseline in patient reported assessment of their osteoarthritis at the time of inquiry. Endpoints for this objective include change from baseline to Week 12 and to Week 24 in Patient Global Assessment score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their Patient Global Assessment scores that are greater than in the placebo group at Weeks 12 and 24. Thus, each treatment with the compound of Formula I is expected to improve osteoarthritis within 12 weeks and until at least 24 weeks after the treatment.
[00132] An additional objective is to explore the effects of single-dose IA administration of the compound of Formula I on the change from baseline in patient reported impression of how their osteoarthritis has changed over the course of the study. Endpoints for this objective include change from baseline to Week 12 and to Week 24 in Patient Global Impression of Change score in patients receiving a single 0.5, 2.0, or 4.0 mg dose of the compound of Formula I versus those receiving placebo. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have improvements in their reported impressions that are greater than in the placebo group. Thus, each treatment with the compound of Formula I is expected to improve a patient’s
impression of how the patient’s osteoarthritis changes within 12 weeks and until at least 24 weeks after the treatment.
[00133] An additional objective is to explore the effects of single-dose IA administration of the compound of Formula I on soluble biomarkers and imaging biomarkers of joint degeneration and repair. An endpoint for this objective includes change from baseline out to Week 24 in serum/plasma and urine biomarkers of synovium, cartilage, and bone degeneration. Another endpoint for this objective is change from baseline to Week 24 in magnetic resonance imaging-based markers of joint structure. Patients receiving the 0.5, 2.0, and 4.0 mg doses are expected to have beneficial changes in serum/plasma and urine biomarkers of synovium, cartilage, and bone degeneration, and in magnetic resonance imaging-based markers of joint structure, that are greater than in the placebo group at Weeks 12 and 24. Thus, each treatment with the compound of Formula I is expected to improve soluble biomarker levels within and until at least 24 weeks after the treatment. Further, each treatment with the compound of Formula I is expected to improve imaging biomarkers of joint degeneration and repair within 12 weeks and until at least 24 weeks after the treatment.
[00134] Overall, the results are expected to indicate that the compound of Formula I is effective, safe, and tolerable in patients with moderate to severe painful knee OA. A single AI dose of the compound of Formula I at, for example, 0.5, 2, or 4 mg, is expected to be effective for achieving each of these results. Each of these results are expected within 12 weeks of treatment, and are expected to last until at least 24 weeks after treatment.
Claims
1. A method of treating a patient diagnosed with osteoarthritis in a j oint comprising administering to the joint a therapeutically effective dose of a compound of Formula I, or a pharmaceutically acceptable salt thereof:
wherein the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound of Formula I results in a decrease in synovitis in the joint.
2. The method of claim 1, wherein the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle.
3. The method of any one of claims 1-2, wherein the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle.
4. The method of any one of claims 1-3, wherein the compound of Formula I is administered intra-articularly to the joint.
5. The method of any one of claims 1-4, wherein the joint is a fern oro-tibial joint.
6. The method of any one of claims 1-4, wherein the joint is a hip.
7. The method of any one of claims 1-4, wherein the joint is spine, shoulder, ankle, wrist, or finger joint.
8. The method of any one of claims 1-7, wherein the therapeutically effective dose of the compound of Formula I is administered as a single dose.
9. The method of any one of claims 1-8, wherein the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months.
10. The method of any one of claims 1-8, wherein the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year.
11. The method of any one of claims 1-8, wherein the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1
year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years.
12. The method of any one of claims 1-11, wherein the patient is > 40 years of age.
13. The method of any one of claims 1-11, wherein the patient is < 85 years of age.
14. The method of any one of claims 1-11, wherein the patient is > 40 and < 85 years of age.
15. The method of any one of claims 1-14, wherein a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
16. The method of claim 15, wherein the baseline measurement is a baseline pain level.
17. The method of claim 16, wherein the baseline pain level is assessed using a pain assessment protocol.
18. The method of claim 17, wherein the pain assessment protocol is an 11-point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC)
Index pain sub scale.
19. The method of any one of claims 15-18, wherein the baseline measurement is a baseline functionality level.
20. The method of claim 19, wherein the baseline functionality level is assessed by WOMAC Index functional sub scale.
21. The method of any one of claims 15-20, wherein the baseline measurement is a baseline radiological categorization.
22. The method of claim 21, wherein the baseline radiological categorization is a Kellgren-Lawrence grade.
23. The method of claim 22, wherein the joint is the fern oro-tibial joint.
24. The method of any one of claims 15-23, wherein the baseline measurement is a baseline synovitis level.
25. The method of claim 24, wherein the baseline synovitis level of the patient is assessed using an 11 point MRI score.
26. The method of any one of claims 1-25, wherein the decrease in synovitis in the joint is measured 12 weeks after the compound of Formula I is administered to the patient.
27. The method of claim 26, wherein the decrease in synovitis is by a decrease of at least 1 point as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
28. The method of claim 27, wherein the decrease in synovitis is by a decrease of at least 4 points, at least 5 points, at least 8 points, at least 9 points, at least 10 points, wherein the decrease is between 1-4 points, between 4-8 points, between 8-10 points, between 10-13 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
29. The method of claim 28, wherein the decrease in synovitis is by a decrease of between 1-4 points as measured by the 11 point MRI score as compared to the baseline synovitis level of the patient.
30. The method of any one of claims 15-29, wherein the baseline measurement is a baseline synovial fluid level.
31. The method of claim 30, wherein the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRI.
32. The method of claims 30 or 31, wherein the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level.
33. The method of claim 32, wherein the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
34. The method of any one of claims 16-33, wherein the therapeutically effective dose of the compound of Formula I further results in a decrease in pain in the joint as compared to the baseline pain level.
35. The method of claim 34, wherein the decrease in pain in the joint is measured 12 weeks or measured 24 weeks after the compound of Formula I is administered to the patient.
36. The method of claim 35, wherein the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11-point NRS.
37. The method of claim 36, wherein the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11 -point NRS.
38. The method of claim 35, wherein the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain sub scale.
39. The method of claim 38, wherein the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain sub scale.
40. The method of claim 35, wherein the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40-50% as measured by the 11 -point NRS or WOMAC Index pain subscale.
41. The method of any one of claims 34-40, wherein the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
42. The method of any one of claims 19-41, wherein the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale.
43. The method of claim 42, wherein the increase in functionality of the joint is measured 12 weeks or 24 weeks after the compound of Formula I is administered to the patient.
44. The method of claim 42, wherein the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points.
45. The method of claim 44, wherein the decrease in the WOMAC Index functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points.
46. The method of any one of claims 15-45, wherein the baseline measurement is a baseline biomarker level.
47. The method of claim 46, wherein the baseline biomarker levels are measured from the patient’s synovial fluid.
48. The method of claims 46 or 47, wherein the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level.
49. The method of claim 48, wherein the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease.
50. The method of any one of claims 46-49, wherein the biomarker comprises MMP-10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C.
51. The method of claims 49 or 50, wherein the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, measured 12 weeks, or measured 24 weeks after the compound of Formula I is administered to the patient.
52. The method of any one of claims 1-51, wherein the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression.
53. The method of any one of claims 46-52, wherein the biomarker comprises a cytokine or chemokine such as CCL20, CCL19, IL-10, or IL-6.
54. The method of any one of claims 46-53, wherein the biomarker comprises IL-6.
55. The method of any one of claims 46-54, wherein the biomarker comprises a growth factor or adhesion molecule such as ICAM-1 or VEGF-C.
56. The method of any one of claims 46-55, wherein the biomarker comprises a protease or protease inhibitor such as MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
57. The method of any one of claims 1-56, wherein the therapeutically effective dose of the compound of Formula I is at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, or more.
58. The method of any one of claims 1-57, wherein the therapeutically effective dose is in at least 8.5 ml, at least 9 mL, at least 10 mL, at least 11 mL, at least 12 mL, or more, of vehicle.
59. The method of any one of claims 1-58, wherein the therapeutically effective dose results in an improved joint architecture measurement.
60. The method of claim 59, wherein a baseline joint architecture measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I, and wherein the improved joint architecture measurement comprises an improvement compared to the baseline joint architecture measurement.
61. The method of claim 59 or 60, wherein the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or X-ray device.
62. The method of claim 60 or 61, wherein the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement.
63. The method of any one of claims 59-62, wherein the joint architecture measurement comprises a cartilage thickness measurement.
64. The method of any one of claims 60-63, wherein the baseline joint architecture measurement comprises a baseline cartilage thickness measurement.
65. The method of claim 64, wherein the cartilage thickness measurement and the baseline cartilage thickness measurement are measured using X-ray or MRI.
66. The method of any one of claims 63-65, wherein the cartilage thickness measurement comprises a joint space width (JSW) measurement.
67. The method of any one of claims 64-66, wherein the baseline cartilage thickness measurement comprises a baseline JSW measurement.
68. The method of claim 67, wherein the improvement comprises an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 mm, or more.
69. The method of any one of claims 63-65, wherein the cartilage thickness measurement comprises a joint space narrowing (JSN) measurement.
70. The method of claim 63 or 64, wherein the baseline cartilage thickness measurement comprises a baseline JSN measurement.
71. The method of claim 70, wherein the improvement comprises reversing, stopping or decreasing the JSN measurement relative to the baseline JSN measurement.
72. The method of any one of claims 59-71, wherein the joint architecture measurement comprises a subchondral bone surface area measurement.
73. The method of any one of claims 60-72, wherein the baseline joint architecture measurement comprises a baseline subchondral bone surface area measurement.
74. The method of claim 73, wherein the improvement comprises a 50 Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the subchondral bone surface area measurement relative to the baseline subchondral bone surface area measurement.
75. The method of claim 73 or 74, wherein the subchondral bone surface area
measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI.
76. The method of any one of claims 59-75, wherein the joint architecture measurement comprises a Kellgren-Lawrence (KL) grade.
77. The method of any one of claims 60-76, wherein the baseline joint architecture measurement comprises a baseline KL grade.
78. The method of claim 77, wherein the improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more.
79. The method of any one of claims 59-78, wherein the joint architecture measurement comprises a progression through a KL grading scale.
80. The method of any one of claims 60-79, wherein the baseline joint architecture measurement comprises a baseline progression through the KL grading scale.
81. The method of claim 80, wherein the improvement comprises a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade, or comprises preventing the progression through the KL grading scale, as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
82. A method of treating a patient diagnosed with osteoarthritis in a joint comprising administering to the joint a therapeutically effective dose of a compound of Formula I, or a pharmaceutically acceptable salt thereof:
wherein the therapeutically effective dose of the compound of Formula I is at least 2 mg in at least 8 mL of vehicle and the therapeutically effective dose of the compound of Formula I results in a decrease in pain in the joint.
83. The method of claim 82, wherein the therapeutically effective dose of the compound of Formula I is at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 6 mg, at least 7 mg, at least 8 mg, at least 9 mg, at least 10 mg, or more.
84. The method of any one of claims 82 or 83, wherein the therapeutically effective dose is in at least 8.5 ml, at least 9 mL, at least 10 mL, at least 11 mL, at least 12 mL, or more, of vehicle.
85. The method of any one of claims 82-84, wherein the therapeutically effective dose of the compound of Formula I is at least 4 mg in at least 8 mL of vehicle.
86. The method of any one of claims 82-85, wherein the therapeutically effective dose of the compound of Formula I is 4 mg in 8 mL of vehicle.
87. The method of any one of claims 82-86, wherein the compound of Formula I is administered intra-articularly to the joint.
88. The method of any one of claims 82-87, wherein the joint is a fern oro-tibial joint.
89. The method of any one of claims 82-87, wherein the joint is a hip.
90. The method of any one of claims 82-87, wherein the joint is spine, shoulder, ankle, wrist, or finger joint.
91. The method of any one of claims 82-90, wherein the therapeutically effective dose of the compound of Formula I is administered as a single dose.
92. The method of any one of claims 82-91, wherein the therapeutically effective dose of the compound of Formula I is administered to the joint every week for two months, or every 2 weeks for two months, or every month for two months.
93. The method of any one of claims 82-91, wherein the therapeutically effective dose of the compound of Formula I is administered to the joint every 3 months for 6 months, every four months for 8 months, every five months for 10 months, every 6 months for 1 year.
94. The method of any one of claims 82-91, wherein the therapeutically effective dose of the compound of Formula I is not administered to the joint for at least 6 months, for at least 1 year, for at least 18 months, for at least 2 years, for at least 3 years, for at least 4 years, for at least 5 years.
95. The method of any one of claims 82-94, wherein the patient is > 40 years of age.
96. The method of any one of claims 82-94, wherein the patient is < 85 years of age.
97. The method of any one of claims 82-94, wherein the patient is > 40 and < 85 years of age.
98. The method of any one of claims 82-97, wherein a baseline measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I.
99. The method of claim 98, wherein the baseline measurement is a baseline pain level.
100. The method of claim 99, wherein the joint pain and/or baseline pain level is assessed using a pain assessment protocol.
101. The method of claim 100, wherein the pain assessment protocol is an 11-point Numeric Rating Scale (NRS) or a Western Ontario and McMaster Universities (WOMAC)
Index pain sub scale.
102. The method of any one of claims 98-101, wherein the baseline measurement is a baseline functionality level.
103. The method of claim 102, wherein the baseline functionality level is assessed by WOMAC Index functional sub scale.
104. The method of any one of claims 98-103, wherein the baseline measurement is a baseline radiological categorization.
105. The method of claim 104, wherein the baseline radiological categorization is a Kellgren-Lawrence grade.
106. The method of claim 105, wherein the joint is the fern oro-tibial joint.
107. The method of any one of claims 98-106, wherein the baseline measurement is a baseline synovial fluid level.
108. The method of claim 107, wherein the baseline synovial fluid level of the patient is measured by physical examination, or by ultrasound, or by MRI.
109. The method of claims 107 or 108, wherein the therapeutically effective dose of the compound of Formula I results in a decrease in synovial fluid in the joint as measured by physical examination, ultrasound, or MRI, as compared to the baseline synovial fluid level.
110. The method of claim 109, wherein the decrease in synovial fluid in the joint is measured 24 weeks, 12 weeks, or 8 weeks, or 4 weeks, or 2 weeks after the compound of Formula I is administered to the patient.
111. The method of any one of claims 82-111, wherein the decrease in pain in the joint is measured 12 weeks, or 24 weeks after the compound of Formula I is administered to the patient.
112. The method of any one of claims 99-111, wherein the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the 11-point NRS.
113. The method of any one of claims 99-112, wherein the decrease in pain in the joint is a change from the baseline pain level of between 2 to 4 points as assessed by the 11 -point NRS.
114. The method of any one of claims 99-111, wherein the decrease in pain in the joint is a change from the baseline pain level of at least 0.5 point, at least one point, at least two
points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points, as assessed by the WOMAC Index pain sub scale.
115. The method of any one of claims 99-114, wherein the decrease in pain in the joint is a change from the baseline pain level of 0.5 point, of 1 point, or of 2 points as assessed by the WOMAC Index pain subscale.
116. The method of claim 111, wherein the decrease in pain in the joint is a change from the baseline pain level of about 50%, 40%, 30%, between 30-40%, or between 40-50% as measured by the 11 -point NRS or WOMAC Index pain subscale.
117. The method of any one of claims 99-116, wherein the decrease in pain relative to the baseline pain level lasts 3 months or more, 4 months or more, lasts 5 months or more, lasts 6 months or more, lasts 7 months or more, lasts 8 months or more, lasts 9 months or more, lasts 10 months or more, lasts 11 months or more, lasts 1 year or more, lasts 2 years or more, lasts 3 years or more, lasts 4 years or more, or lasts 5 years or more.
118. The method of any one of claims 82-117, wherein the therapeutically effective dose of the compound of Formula I results in an increase functionality of the joint as measured by a decrease in the WOMAC Index functionality subscale score relative to the baseline functionality level as measured by the WOMAC Index functionality subscale.
119. The method of claim 118, wherein the increase in functionality of the joint is measured 12 weeks or 24 weeks after the compound of Formula I is administered to the patient.
120. The method of claim 118, wherein the decrease in the WOMAC Index
functionality subscale score is a change from the baseline functionality level of at least 0.5 point, at least one point, at least two points, at least three points, at least four points, at least five points, at least six points, at least seven points, at least eight points, at least nine points, or at least ten points.
121. The method of claim 118, wherein the decrease in the WOMAC Index
functionality subscale score is a change from the baseline functionality level of 0.5 point, of 1 point, of 2 points.
122. The method of any one of claims 98-122, wherein the baseline measurement is a baseline biomarker level.
123. The method of claim 122, wherein the baseline biomarker levels are measured from the patient’s synovial fluid.
124. The method of claims 122 or 123, wherein the therapeutically effective dose of the compound of Formula I results in modulation of a biomarker level relative to the baseline biomarker level.
125. The method of claim 124, wherein the modulation of the biomarker levels relative to the baseline biomarker levels is a decrease.
126. The method of any one of claims 122-125, wherein the biomarker comprises MMP-10, MMP-12, MMP-13, IL-6, IL-10, CCL20, A2M, or VEGF-C.
127. The method of claims 125 or 126, wherein the modulation of the biomarker relative to the baseline biomarker level is measured 4 weeks, measured 8 weeks, or measured 12 weeks after the compound of Formula I is administered to the patient.
128. The method of any one of claims 82-127, wherein the therapeutically effective dose of the compound of Formula I results in the patient’s global impression of change (PGIC) to become much improved or very much improved relative to the patient’s baseline impression.
129. The method of any one of claims 122-128, wherein the biomarker comprises a cytokine or chemokine such as CCL20, CCL19, IL-10, or IL-6.
130. The method of any one of claims 122-129, wherein the biomarker comprises IL-
6
131. The method of any one of claims 122-130, wherein the biomarker comprises a growth factor or adhesion molecule such as ICAM-1 or VEGF-C.
132. The method of any one of claims 122-131, wherein the biomarker comprises a protease or protease inhibitor such as MMP-3, MMP-10, MMP-12, MMP-13, or A2M.
133. The method of any one of claims 82-132, wherein the therapeutically effective dose results in an improved joint architecture measurement.
134. The method of claim 133, wherein a baseline joint architecture measurement is obtained from the patient prior to administering to the joint a therapeutically effective dose of the compound of Formula I, and wherein the improved joint architecture measurement comprises an improvement compared to the baseline joint architecture measurement.
135. The method of claim 133 or 134, wherein the joint architecture measurement is measured using MRI, ultrasound, computed tomography, or X-ray device.
136. The method of claim 134 or 135, wherein the improvement comprises a reversal, slowing, or stopping of an adverse effect on the joint architecture measurement relative to the baseline joint architecture measurement.
137. The method of any one of claims 133-136, wherein the joint architecture measurement comprises a cartilage thickness measurement.
138. The method of any one of claims 134-137, wherein the baseline joint architecture measurement comprises a baseline cartilage thickness measurement.
139. The method of claim 138, wherein the cartilage thickness measurement and the baseline cartilage thickness measurement are measured using X-ray or MRI.
140. The method of claim 138 or 139, wherein the cartilage thickness measurement comprises a joint space width (JSW) measurement.
141. The method of claim 138, wherein the baseline cartilage thickness measurement comprises a baseline JSW measurement.
142. The method of claim 141, wherein the improvement comprises an increase in the JSW measurement relative to the baseline JSW measurement of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0 mm, or more.
143. The method of claim 138 or 139, wherein the cartilage thickness measurement comprises a joint space narrowing (JSN) measurement.
144. The method of claim 138, wherein the baseline cartilage thickness measurement comprises a baseline JSN measurement.
145. The method of claim 144, wherein the improvement comprises reversing, stopping or decreasing the JSN measurement relative to the baseline JSN measurement.
146. The method of any one of claims 133-145, wherein the joint architecture measurement comprises a subchondral bone surface area measurement.
147. The method of claim 146, wherein the baseline joint architecture measurement comprises a baseline subchondral bone surface area measurement.
148. The method of claim 147, wherein the improvement comprises a 50 Hounsfield Unit (HU), 100 HU, 150 HU, 200 HU, 250 HU, 300 HU, 350 HU, 400 HU, 450 HU, 500 HU, or more, increase in the subchondral bone surface area measurement relative to the baseline subchondral bone surface area measurement.
149. The method of any one of claims 146-148, wherein the subchondral bone surface area measurement and the baseline subchondral bone surface area measurement are measured using X-ray or MRI.
150. The method of claims 133-149, wherein the joint architecture measurement comprises a Kellgren-Lawrence (KL) grade.
151. The method of claim 150, wherein the baseline j oint architecture measurement comprises a baseline KL grade.
152. The method of claim 151, wherein the improvement comprises a decrease in the KL grade relative to the baseline KL grade by one KL grade or more.
153. The method of claims 133-152, wherein the joint architecture measurement comprises a progression through a KL grading scale.
154. The method of claim 153, wherein the baseline joint architecture measurement comprises a baseline progression through the KL grading scale.
155. The method of claim 154, wherein the improvement comprises a decrease in a rate of the progression through the KL grading scale relative to a rate of the baseline progression through the KL grading scale grade, or comprises preventing the progression through the KL grading scale, as assessed 3 months or more, 4 months or more, 5 months or more, 6 months or more, 7 months or more, 8 months or more, 9 months or more, 10 months or more, 11 months or more, 12 months or more, 13 months or more, 14 months or more, 15 months or more 16 months or more, 17 months or more, 18 months or more, 2 years or more, 2.5 years or more, 3 years or more, 3.5 years or more, 4 years or more, 4.5 years or more, or 5 years or more after administration of the therapeutically effective dose of the compound of Formula I.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962862672P | 2019-06-17 | 2019-06-17 | |
US62/862,672 | 2019-06-17 | ||
US201962931719P | 2019-11-06 | 2019-11-06 | |
US62/931,719 | 2019-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020257173A1 true WO2020257173A1 (en) | 2020-12-24 |
Family
ID=74037558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/037896 WO2020257173A1 (en) | 2019-06-17 | 2020-06-16 | Method of treating the osteoarthritic joint |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020257173A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120118596A (en) * | 2011-04-19 | 2012-10-29 | 가톨릭대학교 산학협력단 | Composition for prevention or treatment of immune disease comprising nutlin-3a |
WO2015116740A1 (en) * | 2014-01-28 | 2015-08-06 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2017008060A1 (en) * | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
-
2020
- 2020-06-16 WO PCT/US2020/037896 patent/WO2020257173A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120118596A (en) * | 2011-04-19 | 2012-10-29 | 가톨릭대학교 산학협력단 | Composition for prevention or treatment of immune disease comprising nutlin-3a |
WO2015116740A1 (en) * | 2014-01-28 | 2015-08-06 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
WO2017008060A1 (en) * | 2015-07-08 | 2017-01-12 | Unity Biotechnology, Inc. | Compositions and methods for treating senescence-associated diseases and disorders |
Non-Patent Citations (3)
Title |
---|
PARK, JIN-SIL ET AL.: "p53 Controls Autoimmune Arthritis via STAT-Mediated Regulation of the Thl7 Cell /Treg Cell Balance in Mice", ARTHRITIS & RHEUMATISM, vol. 65, no. 4, 2013, pages 949 - 959, XP055396804, DOI: 10.1002/art.37841 * |
ZHANG TING, LI HUIHUA, SHI JUAN, LI SHA, LI MUYUAN, ZHANG LEI, ZHENG LETING, ZHENG DEXIAN, TANG FULIN, ZHANG XUAN, ZHANG FENGCHUN,: "p53 predominantly regulates 1L-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis", ARTHRITIS RESEARCH & THERAPY, vol. 18, no. 1, 24 November 2016 (2016-11-24), pages 271, XP055775737 * |
ZHANG, L ET AL.: "MDM2 promotes rheumatoid arthritis via activation of MAPK and NF-KB", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 30, 2016, pages 69 - 73, XP029369213, DOI: 10.1016/j.intimp.2015.11.030 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hermann et al. | Current treatment options for osteoarthritis | |
Ugurlu et al. | Necrobiotic xanthogranuloma: long-term outcome of ocular and systemic involvement | |
Opoka-Winiarska et al. | Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation | |
Takeuchi et al. | A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis | |
JP2022058550A (en) | Method of alleviating joint pain | |
Hegab et al. | Synergistic effect of platelet rich plasma with hyaluronic acid injection following arthrocentesis to reduce pain and improve function in TMJ osteoarthritis | |
JP5883458B2 (en) | Treatment of bone marrow edema (EDEMA (OEDEMA)) with polysulfated polysaccharides | |
EP3905942A1 (en) | Formulation for use in treating osteoarthritis | |
WO2020257173A1 (en) | Method of treating the osteoarthritic joint | |
Busquets-Pérez et al. | Interstitial granulomatous dermatitis with arthritis (Ackerman syndrome) | |
Tanaka et al. | Effects of needle-arthroscopic lavage with different volumes of fluid on knee synovitis in rheumatoid arthritis | |
WO2020117360A1 (en) | Formulation for use in treating osteoarthritis | |
Du Le Thi Huong et al. | Granulomatous uveitis revealing Wegener's granulomatosis. | |
US20220184180A1 (en) | Treatment of patients at risk of rapid progression of osteoarthritis | |
Sun et al. | Therapeutic effect of shoulder arthroscopic release on frozen shoulder and its effect on fibrogenic cytokines and inflammatory factors | |
US20220226433A1 (en) | Method to Identify Responders to Osteoarthritis Therapeutics | |
JP2013515024A (en) | Combinations for the treatment of osteoarthritis | |
JP6553179B2 (en) | 2- (2-Methylamino-pyrimidin-4-yl) -1H-indole-5-carboxylic acid [(S) -1-carbamoyl-2- (phenyl-) for use in the treatment of pain associated with osteoarthritis Pyrimidin-2-yl-amino) -ethyl] -amide | |
Chuanwen et al. | Effects of Jintiange capsule on MMP-3, TIMP-1, IL-1β, and TGF-β1 levels in synovial fluid of patients with knee osteoarthritis. | |
SVL et al. | Prospective study on assessment of efficacy of etoricoxib versus etoricoxib with combination of glucosamine and chondroitin in primary osteoarthritis of knee | |
CN118201629A (en) | CD 40L-specific TN 3-derived scaffolds for the treatment and prevention of sjogren's syndrome | |
Yao | Intra-articular Injection of Magnesium-containing Solution as an Effective Strategy for Alleviating Osteoarthritis: A Proof-of-Concept Study | |
Shevchuk et al. | AB0191 ENDOTHELIN-1 LEVEL IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME, ITS ASSOCIATION WITH ENDOTHELIAL DYSFUNCTION AND ATHEROSCLEROSIS | |
CN117357629A (en) | Application of polypeptide in preparation of medicine for treating psoriasis | |
Youn et al. | Colchicine treatment in a patient with neutrophilic dermatosis associated with rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20826671 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24.03.2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20826671 Country of ref document: EP Kind code of ref document: A1 |